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ABSTRACT OF CAPSTONE

Epidemiology of Colorectal Cancer Comorbidities and Stage at Diagnosis,
Survival, and Second Primary Malignancies in Kentucky, 2003-2016
Background: Colorectal cancer (CRC) is the third most common type of cancer and the third most
common cause of cancer death among men and women in the United States.1-3 The American Cancer
Society estimates that there will be 147,950 new cases of CRC and 53,200 CRC related deaths in the
U.S. for the year 2020.3 Kentucky CRC incidence for 2012-2016 was the highest in the nation, and the
mortality rate for years 2013-2017 was ranked 5th in the nation.4-6 Risk factors for CRC include
lifestyle factors, genetics, and disease status (comorbidities and treatment).2, 7 Diabetes has been
found to be the most prevalent comorbidity among CRC patients, and the risk of developing CRC in
patients with diabetes is 25% higher than those without diabetes.8, 9

Aim: The purpose of this study is to explore if comorbidities impacts CRC progression, CRC
outcomes, and the development of second primary malignancy among CRC patients age 18 and older
in Kentucky diagnosed between January 1, 2003 and December 31, 2016.

Methods: Two studies were performed using CRC data from Kentucky Cancer Registry, one was a
retrospective cohort study and the other was a case control study. There were 20,571 cases included
in the cohort study with the primary outcomes was all-cause mortality, CRC mortality, and second
primary cancer. There were 18,170 total, 9,085 cases and controls in the second study. This study
examined the geographical distribution of late-stage CRC and comorbidities.

Results Chapter 3: Logistic regression models show that comorbidities increased the odds of death
or late-stage CRC. The Cox proportional hazard models of all-cause and CRC mortalities and second
primary show that comorbidities, patient factors, and treatments can be protective or increase the

hazards of dying or having a second primary cancer. The Kaplan Meier curve demonstrates the
survival of early-stage at diagnosis CRC versus late-stage at diagnosis CRC.

Results Chapter 4: The geographical distribution maps of the four positively associated
morbidities (electrolyte disorders, liver disease, weight loss, and deficiency anemia) do not
demonstrate any patterns resembling the cluster, the comorbidity distribution appears to be random.
The map of comorbidities among CRC patients show that a large percentage experience a burden of
two or more comorbidities.

Conclusion: The results indicate that comorbidities do play a role in the stage of CRC diagnosis, with
the data showing greater odds of being diagnosed with early-stage cancer for many of the individual
comorbidities. The space-time analysis found a significant high rate cluster of late-stage CRC,
however, mapping the distribution of positively associated comorbidities did not demonstrate a
pattern matching the cluster. Further research is needed to examine the impact of comorbidities and
CRC stage at diagnosis.
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Chapter 1
Introduction
Background and Statement of the problem

Colorectal cancer (CRC), includes any cancer that arises in the colon or rectum, the part of the
gastrointestinal system making up the large intestines. CRC is sometimes termed colon cancer, bowel
cancer, or rectal cancer.7 Several decades ago CRC had a low incidence rate, however, it is now the
third most common type of cancer and the third most common cause of cancer death among men
and women in the United States.1-3 The American Cancer Society estimates that in 2020 there will be
147,950 new cases of CRC and 53,200 CRC related death in the U.S..3
Kentucky ranks number one in per capita cancer incidence and mortality rates.5 The risk of
developing any cancer increases with age, the same is true for CRC, older adults (50 years and older)
have the most CRC burden than any age group.3, 10 CRC incidence reported for 2012-2016 in
Kentucky was the highest in the nation at 49.2 (per 100,000) and mortality for years 2013-2017,
Kentucky ranked 5th in the nation with a rate of 16.4 (per 100,000).4-6 Eastern Kentucky, part of the
Appalachia region, makes up about 15% of the population of Kentucky, yet experiences a higher rate
of mortality and morbidity than the rest of the state.5 The area also has high prevalence rates of lung
disease, heart disease, and diabetes.5
While healthcare professional do not know the cause of CRC, there are many known risk
factors associated with CRC.2 Risk factors for CRC include family history, being over the age of 50,
African American race, history of polyps, radiation therapy, inherited and inflammatory diseases, and
lifestyle factors like low physical activity, smoking, alcohol, obesity, and high-fat diets.2, 7 Diabetes has
1

been found to be the most prevalent comorbidity among CRC patients.8, 9 The risk of developing CRC
in patients with diabetes is estimated to be more than 25% higher than those without diabetes.9
There are studies addressing 1) the prevalence of CRC screening and comorbidities within
Appalachian Kentucky and 2) non-adherence to the standard of care as a contributing factor for
Kentucky’s high mortality rate.11, 12 To date, there is no known study that has compared CRC
outcomes and comorbidities across Kentucky.
Purpose of the Study

To address these gaps in the literature, we conducted secondary data analysis on CRC patients
in Kentucky using data from the Kentucky Cancer Registry (KCR). KCR is a population-based central
cancer registry that collects data on cancer, treatment, death, and individual demographic data.
The overarching purpose of the current study is to explore if comorbidities impact CRC
progression, CRC outcomes, and the development of second primary malignancy among CRC patients
age 18 and older in Kentucky diagnosed between January 1, 2003 and December 31, 2016.
There are three specific aims for this study:
1. Aim 1 was to characterize the patient factors of socio-demographic and comorbidity by stage
of diagnosis.
2. Aim 2 was to examine if comorbidity status is associated with mortality and having second
primary cancers.
3. Aim 3 was to perform a space-time cluster analysis of late-stage at diagnosis to investigate its
relationship with comorbidities at the population level.

2

Research hypotheses
H1: CRC patients in Kentucky without comorbidity are more likely to be diagnosed with late-stage
cancer compared to patients with comorbidity.
H0: There is no difference in the diagnosis of late-stage CRC patients in Kentucky with or without
comorbidity.
H2: CRC patients in Kentucky with comorbidity are more likely to be diagnosed with a second primary
malignancy compared to patients without comorbidity.
H0: There is no difference in the diagnosis of second primary malignancy in CRC patients with or
without comorbidity.
H3: CRC patients in Kentucky with comorbidity have higher all-cause mortality compared to patients
without comorbidity.
H0: There is no difference in all-cause mortality in CRC patients with or without comorbidity.
H4: CRC patients in Kentucky with comorbidity have higher CRC mortality compared to patients
without comorbidity.
H0: There is no difference in CRC mortality in CRC patients with or without comorbidity.
H5: High rate late-stage CRC diagnoses in Kentucky will be spatially and temporally correlated with
low rates of CRC morbidity.
H0: There is no spatial or temporal correlation between high rates of late-stage diagnosis and CRC
comorbidities among CRC cases in Kentucky.

3

Significance of the study
This study will add to the extant literature by examining the relationship between comorbidity
and cancer outcomes including survival and development of second primary malignancy across
Kentucky to inform comprehensive prevention programs targeting populations identified at risk. The
results of this study will also be useful for informing future CRC and comorbidity research.
Limitations and delimitations of the study
There are several potential methodological limitations that should be considered when
interpreting data on second primaries when using a population-based cancer registry. One major
limitation is the lack of a standard definition of multiple primaries that can be applied across all
diagnosed cases, a person diagnosed in 2003 would have different classification rules from someone
diagnosed in 2005, 2007, or 2018.13-17 This makes it extremely difficult to be accurate and compare
multiple primaries across years.17 The data set includes second primary according to the rules during
the time period of the diagnosis. The biggest limitation of these data is with regards to changes in the
rules for diagnosis of second primaries during different time periods. Second primaries would not
mean the same thing between those time periods and this would affect the interpretation of the
results. For the study time period 2003-2016, KCR’s multiple primary rules remained relatively
similar. Other potential limitations include not all cases being captured, incomplete data due to
clerical errors, and missing data due to unavailability.18 The missing comorbidities data could be due
to the reality that many reporting hospitals are not part of the Commission of Cancer (CoC), a group
that requires comprehensive standardized data collection.19, 20 Another limitation would be patients
receiving surgery for something other than a malignancy, such as receiving resection of the colon that
may or may not contain cancer, and may or may not be tested because it was removed for other
reasons.
4

Overview of Project Processes
Descriptive statistics were used to compare the socio-demographic and comorbidity factors in
CRC patients included and excluded from the study. Odds ratios and 95% confidence intervals were
estimated from Logistic regression. Multivariable Cox proportional hazard regressions were used to
examine if comorbidity status was associated with CRC survival and second primary malignancy. The
statistical software SAS version 9.4 was used for all of the above analyses.21 The spatial software,
SaTScan and ArcGIS, were also used to perform spatial analysis and visualize the prevalence of
comorbidity among CRC patients in Kentucky.22, 23
Definition of Terms in context of this study
•

Colorectal Cancer (CRC)- an initial primary cancer that arises in the colon or rectum

•

Comorbidity – a chronic health condition in the presence of primary CRC

•

Multi-morbidity – the presence of two or more comorbidities in the presence of primary CRC

•

Second primary malignancy – an additional primary cancer that arises after the first primary
cancer has been diagnosed and treated

•

Kentucky Cancer Registry (KCR) – a population-based registry in Kentucky that collects cancer
related personal health, and treatment information

5

Chapter 2
Literature Review

The purpose of this literature review is to introduce and orient the topics of interest for this
CRC study. The goal is to identify any gaps in knowledge surrounding CRC, comorbidities, and the use
of spatial analysis to view disease distribution over a geographical area.
Cancer Surveillance
Cancer surveillance is the routine continuous systematic collection and analysis of data on
new cancer incidences, morbidity, treatment, survival, and mortality.24, 25 Cancer surveillance
quantifies the incidence of cancer and its related factors (e.g., genetic or behavioral factors) in a
defined population to provide a means by which the observations can be used in research to facilitate
interventions and reduce the burden of cancer.24, 25 Cancer surveillance, like that of other Public
Health Surveillance programs have strict inclusion criteria that could include diagnosis, timing, and/or
be laboratory confirmed to be considered a case, while a clinical diagnosis may not be as involved for
a patient to receive the diagnosis and treatment.26
In the United States there is no nationally recognized single surveillance program.25 While
there are several smaller registries that are created from doctors’ offices, hospital and healthcare
system registries, to state population-based registries, there are two important national cancer
surveillance programs, National Program of Cancer Registries (NCPR) and The Surveillance,
Epidemiology and End Results Program (SEER).25
In Kentucky, the state cancer registry, Kentucky Cancer Registry (KCR), began as a voluntary
reporting system until legislation mandated reporting starting in 1991.27 KCR is funded by NPCR and
SEER. Data collected by KCR is sent to the umbrella organization, North American Association of
6

Central Cancer Registries (NAACR) to be independently evaluated for completeness, accuracy, and
timeliness.20, 27 Kentucky Cancer registry is very thorough, and among the most accurate and
complete population-based registries.27
Colorectal Cancer
CRC, includes any cancer that initiates in the colon or rectum, the portion of the
gastrointestinal system that makes up the majority of the large intestines, other names for CRC are
colon cancer, bowel cancer, or rectal cancer.7 The anus is the final part of the large intestine but
because of the cell types are different that make up the anus, any cancers originating in the anus is
classified as anal cancer.3 The colon is made up of four sections, the ascending colon, transverse
colon, descending colon, and the sigmoid colon, it is about 5 feet long and is connected at the bottom
to the rectum.3 There are three functions of the large intestine including absorption of electrolytes
and water from food being digested, production and absorption of vitamins, and the formation and
elimination of fecal waste from the body.3, 28
CRC is ranked third for most commonly diagnosed cancer and it is also the third leading cause
of cancer death in both men and women.3 While there are no certain causes of CRC, there are many
known risk factors.2 Risk factors for CRC include advanced age, African American race, history of
polyps, family history of colon cancer, sedentary lifestyle, high-fat diet, diabetes, obesity, smoking,
radiation therapy, alcohol, and inherited and inflammatory diseases.2, 7
Patient Factors
Age
The median age at diagnosis for rectal cancer is 63 years old and median age of diagnosis for
colon cancer is 68 in men and 72 in women.29 The majority of CRCs are diagnosed in people over the
age of 50, with only around 12% being diagnosed in people under the age of 50.3 The incidence of
7

CRC in patients under the age of 50 has been increasing, however healthcare providers are not sure
the reason behind the increase.2, 10 One author found that patients diagnosed at younger than 50
years of age presented with advance stage and higher recurrence of CRC than older patients but the
two groups had comparable survival.10 Right-sided colon cancer seems to be more prevalent in older
adults and women and this type of CRC usually presents at more advanced stages with lower survival
rate.30
Sex
The lifetime risk of developing cancer is similar in both men and women, about 1 in 23 men
and 1 in 25 women, a difference of 0.3% incidence.7 Socioeconomic factors seem to
disproportionately affect CRC incidence rates in men. One study from England found that the most
deprived areas had a 13% higher incidence rate compared to the least deprived areas; there was no
difference found in women.31 The author also noted that men are less aware of cancer signs and
symptoms compared to women.31 Another study noted that genetic and environmental factors are
believed to play a role in sex-associated differences in CRC, with high-fat diet being associated with
the risk and development on CRC.32 The biological responses to diet are different among men and
women.32 Studies have associated women with a higher proportion of right-sided colon cancer,
which usually presents at a more advanced stage, which might account for women having a lower 5year survival rate.30, 32
Second Primary
A second primary is a new primary cancer that arises in a person that has had a diagnosis and
treatment for a non-related cancer in the past.33 Second primaries comprise almost 19% of incident
cancer cases.34 Patients can have multiple primaries, the requested data included the number of
primary cancers, including the first primary cancer of CRC. Patients that have had CRC often have
8

several health problems, including a higher risk of secondary cancers.34, 35 People that have had colon
or rectal cancers can develop any second primary cancer but are at an increased risk of developing
colon, rectal, stomach, small intestine, anal, or lung cancer.35, 36 While the risk of secondary primary
cancers is complex, genetics, previous cancer treatments, and environmental exposures have been
recognized as risks to developing a second primary.34, 37
Comorbidities
Elixhauser groups
A comorbidity is defined as a disease or condition that exists simultaneously with another
index condition of interest.38, 39 The presence of comorbidity in addition to an index condition such as
cancer has become increasingly more common with much evidence supporting the majority of the
comorbidity burden is concentrated in patients that are older, those in minority groups, and those
patients living in poverty-stricken areas.39 The presence of comorbidities varies by cancer site and is
difficult to determine an accurate prevalence.38, 39 Comorbidity is usually assessed as a contributor to
a health outcome, like cancer survival, using methods such as individual disease indexes or counts
and weighted grouped variables to help describe overall disease burden and health status of a
patient.38, 40
In this study, comorbidities will be looked at both on an individual level and an index, using
the Elixhauser comorbidity index. The Elixhauser comorbidity index includes 29 individual comorbid
conditions that were initially selected and refined by examining the literature.41-43 The final use of
the Elixhauser index was modified to only include 26 groupings. Diabetes with and without chronic
complications was combined into one group. Three of the groupings, metastatic cancer, lymphoma,
and solid tumor without metastasis were not evaluated. Although the Kentucky Cancer Registry
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captures these data, these cancers should not be considered comorbid conditions as part of the index
since the disease of interest is also cancer.
Prior to the newest Elixhauser measure, there were 31 groupings, the updated version has
since collapsed hypertension (complicated and uncomplicated) and removed cardiac arrhythmias, as
research has shown cardiac arrhythmia was not a good indicator of readmission, and questions
remain around its reliability as a comorbidity.41, 44 The older Elixhauser measure that used ICD-9-CM
diagnosis codes was converted to the new Elixhauser version, which utilized ICD-10-CM codes, and
combined according to Agency for Healthcare Research and Quality’s (AHRQ) guidelines.41, 45
Traditionally the Elixhauser index has been used in research as a count index, more eligible diagnoses
would lead to a higher count and risk to the patient.46-48 This index, like the Charlson Comorbidity
index, has been used to predict in-hospital mortality, high-risk patients, and scenarios that may need
a higher intervention of care both while in the hospital and when transitioning out of the hospital to
prevent readmissions.44, 45, 49 One study found that using the individual Elixhauser comorbidities in a
regression gave slightly better results compared to the Elixhauser index score and it is possible “that a
comorbidity measure with more variables can lose more information than one with a smaller number
of variables in finite sample sizes”.48 While the index score is important to use, the objective of this
study is not focused on hospital utilization and readmission; the individual and grouped comorbid
conditions are more important to use in this study.
Colorectal cancer and comorbidities
A number of studies have shown that cancer patients with comorbidity have lower survival
compared to cancer patients without comorbidity.50 Although the pattern of comorbidities and their
risk factors among CRC patients is not well documented globally, there is however, consistent
evidence illustrating the effect of comorbidities on CRC outcomes.8 Morbidities are often associated
10

with the elderly, but have recently been occurring in younger patients living in socioeconomically
deprived areas.51 A study of adults with hypertension found that in a year of visits with their primary
care provider, only one third were related to hypertension while the next most common reason for
their care visit was for diabetes.51 Studies have found that morbidities, both physical and mental
health conditions, do not exist in isolation and are influenced by an individuals’ society and family.8, 51
Studies have found that diabetes is the most prevalent comorbidity among CRC patients.8, 9 The risk
of CRC in patients with diabetes is estimated to be more than 25% higher than those without
diabetes.9
Another study found that CRC patients can be grouped into four classes based on defined
clusters of comorbid conditions.40 Class one represented the largest part of the sample and included
patients with no Charlson-defined comorbidities or only one morbidity.40 Classes two and three
were similar in size and age at diagnosis, however class two patients comorbid conditions were
primarily characterized as cardiovascular or cardiorespiratory diseases, while class three comorbid
conditions were primarily diabetes with complications such as kidney disease.40 Class four consisted
of less than 8% of the study population and were comprised of the patients with the presence of four
or more comorbidities.40 Class one patients had the highest survival probability followed by class
three, class two, and then class four, with the lowest survival probability -- 43% lower than class
one.40 The majority of class four patients were older with a higher burden of comorbidity.40 Despite
the increasing importance of comorbidity among cancer patients, many challenges and questions
remain.50 Cancer patients with comorbidities have compromised treatment plans, effectiveness, and
compliance, and we do not know the duration and severity of the influence of comorbidity on cancer
prognosis or how comorbidity is most accurately measured in cancer patients.50, 52
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Geospatial topics
Appalachia
The Appalachian region includes all of West Virginia and parts of 12 other states, including 54
counties in the southeastern and eastern area of Kentucky.53, 54 Within the Appalachian region, and
more specifically rural Appalachia, health disparities have been well documented.53 Appalachia as a
whole experiences higher rates of mortality and chronic diseases such as diabetes, chronic
obstructive pulmonary disease, heart disease, stroke, and cancers such as lung, breast, and CRCs than
non-Appalachian areas.53-55 Health disparities and disease in Appalachia are exacerbated by
socioeconomic, behavioral, and geographical factors such as environmental exposures, poverty, low
literacy rates, lack of health insurance coverage, long distances from home to clinics and healthcare
providers, high rates of obesity and smoking, low physical activity, and many other multifactorial
issues.53, 55 Appalachia has high rates of CRC incidence and mortality and CRC is one of the leading
causes of cancer deaths in Appalachia in both men and women.56, 57

Interaction of patient factors and geospatial data
Geographic information systems (GIS) are used in epidemiological research to identify the
“where” of disease.58 Spatial data in public health studies allows for researchers to visualize disease
and patient attributes across geographic areas which can help to identify and characterize health
trends over time.59, 60 Spatial analysis of patient data can help to determine clustering or patterns in
geographic areas that will help to understand patient populations at higher risk, determine any
socioeconomic factors, and highlight areas that would need intervention in addressing health
disparities.59, 60 Cluster analysis is useful in producing estimates where limited data is available and
providing statistical evidence of diseases.58 Creating maps based on disease information more easily
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reveals geographic-related information about disease distribution than typical research tables
showing data.58
Utilizing SaTScan in this study to perform a cluster analysis was helpful in detecting areas with
high or low rates of statistical significance during time period, 2003-2016.22 SaTScan was required to
perform the analysis because it is not available in standard GIS software packages.61 For mapping
purposes, the resulting cluster analysis from SaTScan was exported and layered with a map of
Kentucky in ArcGIS 10.7.1.62 ArcGIS was also used to map the proportion of comorbidities and latestage cancers within each county.23 These maps are necessary for us to visualize the geographic
distribution of these factors and evaluate them relative to one another.
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Chapter 3
Paper 1: The Effect of Comorbidities on Colorectal Cancer Stage at Diagnosis,
Mortality, and Second Primary Cancers among Colorectal Cancer Cases in Kentucky
(2003-2016)
Background
Colorectal cancer (CRC) is cancer that begins in the colon or rectum, the portion making up
the large intestines of the gastrointestinal system, other names are colon cancer, bowel cancer, or
rectal cancer.7 CRC is the third most common type of cancer and the third most common cause of
cancer death among men and women in the United States.1-3 By 2020, The American Cancer Society
estimates that there will be 147,950 new cases of CRC and 53,200 CRC related death in the U.S..3
Kentucky ranks number one in overall cancer per capita incidence and mortality rates.5 Kentucky had
the highest CRC incidence in nation with 49.2 (per 100,000) for years 2012-2016 and ranked 5th in the
nation in CRC mortality at a rate of 16.4 (per 100,000) for years 2013-2017.3-6
Eastern Kentucky, consisting of much of Kentucky’s Appalachia region, is estimated to
include slightly under 15% of the population of the state, yet the poverty-stricken area experiences a
higher rate of mortality and morbidity than the rest of the state and the nation.5 The area is also
known for its high prevalence rates of chronic illnesses such as lung disease, heart disease, and
diabetes.5
A comorbidity is defined as a chronic illness that exists concurrently with an index condition of
interest.38, 39 In this study, the index condition is primary CRC. The presence of comorbidity in
addition to an index condition, like CRC has become increasingly more common with considerable
evidence supporting a larger part of the burden is concentrated in older patients, minority groups,
and patients living in poverty-stricken or deprivation areas.39
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The presence of comorbidity can vary by cancer site making it difficult to determine an
accurate prevalence.38, 39 In this study, comorbidities will be examined on an individual level as well
as aggregated into groups, using the Elixhauser comorbidity index. The Elixhauser comorbidity index
includes 29 individual comorbid conditions, that were grouped according to similar body systems (i.e.
grouping acute heart failure with chronic heart failure in the congestive heart failure group) reference
table 1-1.41, 42 Comorbidity is usually assessed as a contributor to health outcomes, like cancer
survival, using methods such as individual disease indexes or scores and weighted grouped variables
to help describe a patient’s overall disease burden and health status.38, 40 As such, the Elixhauser
index was chosen for use in the current study.
The exact cause of CRC is not known, however there are many known risk factors associated
with CRC.2 The risk associated with developing any cancer increases with age, the same is true for
CRC, older adults (50 years and older) have the most CRC burden than any age group.3, 10 Other
known risk factors for CRC include family history of CRC, being of African American race, history of
polyps, history of radiation therapy, other inherited and inflammatory diseases, and lifestyle factors
like low physical activity, smoking, alcohol, obesity, and high-fat diets.2, 7 Diabetes has been found to
be the most prevalent comorbidity among CRC patients.8, 9 The risk of developing CRC in patients
with diabetes is estimated to be more than 25% higher than those without diabetes.9
The purpose of this study is to explore if comorbidities impact CRC progression, CRC
outcomes, and the diagnosis with a second primary malignancy among CRC patients aged 18 and
older in Kentucky diagnosed between January 1, 2003 and December 31, 2016. There are two specific
aims for this study. Aim 1 was to characterize patient factors of socio-demographic and comorbidity
by stage of diagnosis. Aim 2 was to examine whether comorbidity status is associated with stage at
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diagnosis, mortality, and the development of second primary cancers. To our knowledge, this will be
the first study that has compared CRC outcomes and comorbidities across Kentucky.

Methods
Study Design and Data Source
This is a retrospective cohort study of CRC cases in Kentucky. We started out with 28,229
incident cases of first primary CRC diagnosed between January 1, 2003 and December 31, 2016 and
excluded a combined total of 7,658 cases due to missing information. The excluded cases included
6,054 because of missing morbidity information and 2,730 (1,126 of these were also missing
morbidity information and included in the above number) because of missing stage. The final study
population included 20,571 CRC cases. Table 1-2 compares included and excluded cases. All cases
were identified from the Kentucky Cancer Registry (KCR). KCR is funded in part by Surveillance,
Epidemiology, and End Results Program (SEER) and National Program of Cancer Registries (NCPR),
and North American Association of Central Cancer Registries (NAACR).20, 27 KCR data is sent to the
umbrella organization, North American Association of Central Cancer Registries (NAACR) to be
independently evaluated for completeness, accuracy, and timeliness. Approval for this study was
granted by the University of Kentucky Internal Review Board.

Variables
Sex, age at diagnosis, race, ethnicity, marital status at diagnosis, number of primaries, survival
for primary and a subsequent second primary, Appalachian status, vital status, primary payer, best
stage group, treatment composite, comorbidity (up to 10 independent variables of ICD-9-CM
diagnosis codes), and secondary diagnosis (up to 10 independent variables of ICD-10-CM diagnosis
codes) were provided by KCR. Age at diagnosis was categorized into five age groups, 18 - 34, 35 - 44,
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45 – 54, 55 – 64, and 65+ years. Number of primaries was coded as 0 for the initial CRC primary of
interest and 1 for any patient that had been diagnosed for any subsequent primaries not related to
their initial primary of CRC. Race was categorized as white, black, and other. Ethnicity was categorized
as non-Hispanic or Hispanic. Marital status at diagnosis was categorized at married, single, or other.
Primary payer was categorized as Medicaid, Medicare, military/other, private pay, and not insured.
The variable treatment had 15 combinations of treatment, including no treatment, and variations of
surgery, radiation therapy, chemotherapy, and other therapies. The other therapies were not
expressly specified, but typically include immunotherapy. Treatment coding in this study was based
on the available dataset and a CRC study by Rane et al.63 The final coding included six classes: no
treatment, surgery at primary site only, chemotherapy only, radiation only, chemotherapy and
radiation, and surgery at primary site and chemotherapy/or radiation.
Comorbidity was measured using the diagnosis codes from the variables comorbidity and
secondary diagnosis and entering into the Elixhauser Comorbidity Software, Version 3.7 for ICD-9-CM
and the Elixhauser Comorbidity Software for ICD-10-CM from Healthcare Cost and Utilization Project
by the Agency for Healthcare Research and Quality.41, 45 The software classifies certain diagnoses
codes as part of the Elixhauser Comorbidity index, outputting individual variables for the 31 (Version
3.7)/29 Elixhauser groups. The final variables were combined to match the most up-to-date
Elixhauser index, removing arrhythmias and combining hypertension.41 Elixhauser groups related to
cancer, solid tumors without metastases, metastatic cancer, and lymphoma were removed. Cancer is
the outcome of interest, and therefore it cannot be a comorbidity. Diabetes with and without chronic
complications were combined after observing some patients had both diagnosis codes.
The Adult Comorbidity Evaluation-27 (ACE-27) index morbidity groupings were considered,
however, available data only includes diagnosis codes, indicating the presence of disease but not
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disease severity.64 ACE-27 grades the extent of organ decompensation on three grades of severity,
mild, moderate, and severe, data from KCR did not allow for measurement of such
decompensation.65 Nonetheless, studies have also shown that the Elixhauser measure performs
better than other comorbidity indexes.46, 48, 49, 66 Table 1-1 shows the morbidity mapping from ACE27 and Elixhauser Comorbidity index to the final inclusion of comorbidities (individual and grouped).
The KCR variables with diagnoses codes include coding for patients with no known morbidities
(comorbidity diagnosis code of 0000 or a secondary diagnosis entry of 0). Patients with these entries
in any diagnoses code variables were treated as having no morbidity. Patients with diagnosis code(s)
in the comorbidity/secondary diagnosis variables that are not part of the Elixhauser groups were also
treated as having no morbidity. Cases with unknown morbidity status and unknown stage at
diagnosis were excluded from the study. Figure 1-1 shows flow chart for case inclusion within the
study.

Statistical Analysis
All analyses were carried out with SAS 9.4 statistical software.21 Included and excluded
patients were compared on demographic and disease characteristics using column percentages to
observe comparisons between groups (see Table 1-2). Included patient demographic characteristics
stratified by cancer stage, early and late using row percentages as comparison can be found in Table
1-2b.
To explore the relationship between morbidities, stage, and survival, a series of bivariate
models were fitted. Two logistic regression models were fitted (tables 1-3 and 1-4), one with stage at
diagnosis (late versus early) and the other with vital status (died versus alive). A cancer specific
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survival model was estimated using Cox proportional hazard regression. Kaplan-Meier survival curves
for primary CRC survival were also analyzed using SAS 9.4 software and can be found in figure 1-2.21
Next, a series of multivariable fully adjusted statistical models for estimating the risk of
mortality or second primary were specified. These models were Cox proportional hazard models that
were fitted to explore the relationship between patient factors and morbidities on survival and
second primary malignancy. The first set of three Cox proportional hazard models looked as all-cause
mortality and can be found in table 1-6. The second set of three Cox proportional hazard models
looked as CRC-cause mortality and can be found in table 1-7. The third set of three Cox proportional
hazard models looked at second primary cancer and can be found in table 1-8. The three sets of
models included sociodemographic data, cancer stage, and followed different categories of
Elixhauser comorbidities; Model 1 used the individual Elixhauser morbidities, Model 2 used Elixhauser
grouped comorbidities based on Table 1-1, and then Model 3 used a total count of the number of
morbidities that a patient would have (no morbidities/0, one morbidity/1, or comorbidities/2+).
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Table 1-1. Morbidity Mapping ACE-27 Index, Elixhauser, and Final Inclusion Study Comorbidity and
Groupings
Ace-27 Index

Elixhauser ICD 10*

Final Inclusion

Cardiovascular System
Congestive Heart Failure
Cardiovascular System
Myocardial Infarct
Valvular disease
Congestive Heart Failure
Angina / Coronary Artery Disease
Pulmonary circulation disorders
Hypertension
Congestive Heart Failure (CHF)
Peripheral vascular disease
Peripheral Vascular Disorder
Arrhythmias
Hypertension (Complicated &
Valvular Heart Disease
Hypertension
Uncomplicated)
Respiratory System
Venous Disease
Paralysis
Pulmonary Circulation Disorders
Peripheral Arterial Disease
Other neurological disorders
Chronic Pulmonary
Chronic pulmonary disease
Respiratory System
Gastrointestinal System
Diabetes Uncomplicated
Restrictive Lung Disease or COPD
Liver Diseases
Diabetes Complicated
Other markers not diagnoses
Peptic Ulcer Disease
Hypothyroidism
Gastrointestinal System
Renal System
Renal failure
Hepatic
Renal Failure
Liver disease
Stomach / Intestine
Endocrine System
Chronic peptic ulcer disease
Pancreas
Diabetes (Complicated & Uncomplicated)
HIV and AIDS
Hypothyroidism
Renal System
Lymphoma
End-stage renal disease
Neurological System
Metastatic cancer
Endocrine System
Paralysis
Solid tumor without metastasis
Other Neurological Disorders
Diabetes Mellitus
Rheumatoid arthritis/ collagen vascular
Neurological System
Psychiatric
diseases
Stroke
Psychoses
Coagulation deficiency
Dementia
Depression
Obesity
Paralysis
Rheumatologic
Weight loss
Neuromuscular
Rheumatoid Arthritis/Collagen
Fluid and electrolyte disorders
Psychiatric
Immunological System
Recent suicidal attempt
Blood loss anemia
AIDS/HIV
Schizophrenia
Deficiency anemias
Substance Abuse
Depression or bipolar disorder
Alcohol abuse
Alcohol Abuse
Rheumatologic
Drug abuse
Drug Abuse
Rheumatoid Arthritis
Psychoses
Body weight
Systemic Lupus
Depression
Obesity
Mixed Connective Tissue Disorder
Blood System
Polymyositis
Coagulopathy
Rheumatic Polymyositis
Blood Loss Anemia
Immunological System
Deficiency Anemia
AIDS
Remain but not grouped
Malignancy
Weightloss
Solid Tumor including melanoma
Leukemia and Myeloma
Fluid & Electrolyte Disorders
Lymphoma
Substance Abuse
Alcohol
Illicit Drugs
Body Weight
Obesity
*Elixhauser ICD-9 (31 Variables) conversion to ICD-10 (29 Variables) version changes: Removal of Cardiac Arrhythmia and
Combining of Hypertension with and without complications. Some data were collected prior to the 2015 ICD-10 activation,
combination and conversion of ICD-9 and ICD-10 Elixhauser adjustment occurred.
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Figure 1-1. Flow chart for participant selection and inclusion/exclusion criteria for study.

21

Table 1-2. Inclusion and Exclusion Demographics (Percentage based on Columns)

Variables
Age
18 - 34 years
35 - 44 years
45 - 54 years
55 - 64 years
65+ years
Marital Status
Missing
Married
Single
Other
Sex
Female
Male
Missing
Race
White
Black
Other
Ethnicity
Non-Hispanic
Hispanic
Missing
Vital Status
Alive
Dead
Stage
Early
Late
Unknown
Appalachian
Diabetes
Renal Failure
Liver Disease
CHF
Hypertension
Total
Comorbidity
Groups
0
1
2+
Unknown
Primary Payer
Missing
Medicaid
Medicare
Military/Other

Inclusion Group N(%)
Early Stage
Late Stage
Total
(N=11,387)
(N=9,184)
Included
(N=20,571)
120 (1.05%)
447 (3.93%)
1,635 (14.36%)
2,720 (23.89%)
6,465 (56.78%)

168 (1.83%)
498 (5.42%)
1,522(16.57%)
2,343(25.51%)
4,653(50.66%)

238 (2.09%)
6,618(58.12%)
1,159(10.18%)
3,372(29.61%)

193 (2.10%)
5,130(55.86%)
1,053(11.47%)
2,808(30.57%)

5,540 (48.65%)
5,846 (51.34%)
1 (0.009%)

4,407(47.99%)
4,777(52.01%)
0

10,518(92.37%)

Probability
Distribution
Between
Groups

3,384 (55.90%)

112 (4.10%)
177 (6.48%)
468 (17.14%)
551 (20.18%)
1,422(52.09%)

509 (8.41%)
3,010(49.72%)
553 (9.13%)
1,982(32.74%)

223 (8.17%)
1,308(47.91%)
305 (11.17%)
894 (32.75%)

9,947 (48.354%)
10,623(51.641%)

2,920(48.23%)
3,134(51.77%)
0

1,369(50.15%)
1,361(49.85%)
0

3,749(48.96%)
3,909(51.04%)
0

p = 0.371

8,464(92.16%)
653 (7.11%)
67 (0.73%)

18,982 (92.28%)

5,604(92.57%)
271 (4.48%)
179 (2.96%)

2,428(88.94%)
215 (7.88%)
87 (3.19%)

7,045(92.0%)
418 (5.46%)
195 (2.55%)

p <0.001

11,236(98.68%)

23 (0.20%)
128 (1.12%)

9,092(98.99%)
30 (0.33%)
62 (0.68%)

20,328 (98.82%)

53 (0.26%)
190 (0.92%)

5,966(98.55%)
19 (0.31%)
69 (1.14%)

2,664(97.58%)
10 (0.37%)
56 (2.05%)

7,545(98.52%)
23 (0.30%)
195 (2.55%)

p = 0.532

6,999 (61.46%)
4,388 (38.54%)

3,010(32.77%)
6,174(67.23%)

10,009 (48.66%)
10,562 (51.34%)

2,657(43.89%)
3,397(56.11%)

1,181(43.26%)
1,549(56.74%)

3,450(45.05%)
4,208(54.95%)

p <0.001

11,387 (100%)
0
0
3,045(26.74%)
2169 (19.05%)
412 (3.62%)
287 (2.52%)
834 (7.32%)
5384 (47.28%)

0
9,184 (100%)
0
2,593(28.23%)
1653 (18.00%)
290 (3.16%)
328 (3.57%)
601 (6.54%)
4053 (44.13%)

11,387(55.35%)
9,184 (44.65%)

5638(27.41%)
3822 (18.58%)
702 (3.41%)
615 (2.99%)
1435 (6.98%)
9437 (45.88%)

2,934(48.46%)
1,994(32.94%)
1,126(18.60%)
2,708(44.73%)
-

0
0
2,730 (100%)
855 (31.32%)
198 (7.25%)
43 (1.58%)
32 (1.17%)
133 (4.87%)
565 (20.70%)

2,934(38.31%)
1,994(26.04%)
2,730(35.65%)
3162(41.29%)
198(2.59%)
43 (0.56%)
32 (0.42%)
133 (1.74%)
565 (7.38%)

3,107 (27.29%)
3,097 (27.20%)
5,183 (45.51%)
0

2,382(25.94%)
2,443(26.60%)
4,359(47.45%)
0

5,489 (26.68%)
5,540 (26.93%)
9,542 (46.39%)
0

0
0
0
6,054 (100%)

650 (23.81%)
405 (14.84%)
549 (20.11%)
1,126(41.25%)

650 (8.49%)
405 (5.29%)
549 (7.17%)
6,054(79.05%)

58 (0.51%)
642 (5.64%)
6,538 (57.42%)
96 (0.84%)

55 (0.60%)
699 (7.61%)
4,823(52.52%)
112 (1.22%)

113 (0.55%)
1,341 (6.52%)

601 (9.93%)
429 (7.09%)
3,168(52.33%)
42 (0.69%)

420 (15.38%)
159 (5.82%)
1,205(44.14%)
43 (1.58%)

617 (8.06%)
538 (7.03%)
3,975(51.91%)
75 (0.98%)

3,157 (15.35%)
5,063 (24.61%)
11,118 (54.05%)

431 (2.10%)

11,748 (57.11%)

2,212(10.75%)
6,180(30.04%)

1 (0.005%)

1,445 (7.02%)
144 (0.70%)

0

11,361 (55.23%)

208 (1.01%)
732 (3.56%)

174 (2.27%)
398 (5.20%)

χ2

90 (1.49%)
276 (4.56%)
925 (15.28%)
1,379(22.78%)

792 (6.96%)
77 (0.68%)

288 (1.40%)
945 (4.59%)

Exclusion Group N(%)
Unknown
Unknown
Total
Comorbidity
Stage
Excluded
(N=2,730)
(N=7,658)
(N=6,054)

1,214(15.85%)
1,712(22.36%)
4,160(54.32%)

560 (7.31%)

3,880(50.67%)

750 (9.79%)

p <0.001

p <0.001

2,468(32.23%)

p <0.001
p <0.001
p <0.001
p <0.001
p <0.001
p <0.001
p <0.001

p <0.001

p = 0.0004
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Not insured
Private Payer
Number of
Primaries
1
2 or more
Survival
Interval
1 year
2 years
3 years
4 years
5 years
> 5 years
Year of
diagnosis
2003 – 2009
2010 - 2016
Survival
Interval
2nd Primary
1 year
2 years
3 years
4 years
5 years
> 5 years
No2nd primary

310 (2.72%)
3,743 (32.87%)

422 (4.59%)
3,073(33.46%)

6,816 (33.13%)

237 (3.91%)
1,577(26.05%)

60 (2.20%)
843 (30.88%)

274 (3.58%)
2,184(28.52%)

9,475 (83.21%)
1,912 (19.76%)

8,217(89.47%)
967 (10.53%)

2,879 (14.00%)

17,692 (86.00%)

5,248(86.69%)
806 (13.31%)

2,419(88.61%)
311 (11.39%)

6,658(86.94%)
1,000(13.06%)

1,452 (12.75%)
1,197 (10.51%)
1,171 (10.28%)
1,170 (10.27%)
1,033 (9.07%)
5364 (47.11%)

2,874(31.29%)
1,634(17.79%)
1,097(11.94%)
802 (8.73%)
606 (6.60%)
2171 (23.64%)

4,326 (21.03%)
2,831 (13.76%)
2,268 (11.02%)
1,972 (9.59%)
1,639 (7.97%)
7535 (36.63%)

2,133(35.23%)
878 (14.5%)
545 (9.00%)
407 (6.72%)
340 (5.62%)
1751(28.92%)

1,096(40.15%)
345 (12.64%)
222 (8.13%)
187 (6.85%)
121 (4.43%)
759 (27.80%)

2,615(34.15%)
1,086(14.18%)
696 (9.09%)
531 (6.93%)
428 (5.59%)
2302(30.06%)

5,701 (50.07%)
5,686 (49.93%)

4,320(47.04%)
4,864(52.96%)

10,021 (48.71%)
10,550 (51.29%)

3,409(56.31%)
2,645(43.69%)

1,484(54.36%)
1,246(45.64%)

4,263(55.67%)
3,395(44.33)

850 (7.49%)
234 (2.05%)
179 (1.57%)
136 (1.19%)
105 (0.92%)
408 (3.58%)
9,475 (83.21%)

587 (6.39%)
85 (0.93%)
71 (0.77%)
57 (0.62%)
37 (0.40%)
130 (1.42%)
8,217(89.47%)

1,437 (6.99%)
319 (1.55%)
250 (1.21%)
193 (0.94%)
142 (0.69%)
538 (2.62%)

375 (6.19%)
92 (1.52%)
67 (1.11%)
57 (0.94%)
46 (0.76%)
169 (2.79%)
5,248(86.69%)

154 (5.64%)
30 (1.10%)
23 (0.84%)
24 (0.88%)
17 (0.62%)
63 (2.31%)
2,419(88.61%)

473 (6.18%)
113 (1.48%)
82 (1.07%)
71 (0.93%)
53 (0.69%)
208 (2.72%)
6,658(86.94%)

17,692 (86.00%)

p = 0.042

p <0.001

p <0.001

p = 0.287
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Table 1-3. Patient Demographics (Percentage based on rows)
Demographics
Age
18 - 34 years
35 - 44 years
45 - 54 years
55 - 64 years
65+ years
Marital Status
Missing
Married
Single
Other
Gender
Female
Male
Missing
Race
White
Black
Other
Ethnicity
Non-Hispanic
Hispanic
Missing
Vital Status
Alive
Dead
Appalachian
Diabetes
Renal Failure
Liver Disease
CHF
Hypertension
Total Comorbidity Groups
0
1
2+
Primary Payer
Missing
Medicaid
Medicare
Military / Other
Not insured
Private Payer
Number of Primaries
1
2 or more

Early Stage (0-II)
Percent
N=11387

Late Stage (III – IV)
N=9184

Percent

120
447
1,635
2,720
6,465

41.67%
47.30%
51.79%
53.72%
58.15%

168
498
1,522
2,343
4,653

58.33%
52.70%
48.21%
46.28%
41.85%

238
6,618
1,159
3,372

55.22%
56.33%
52.40%
54.56%

193
5,130
1,053
2,808

44.78%
43.67%
47.60%
45.44%

5,540
5,846
1

55.70%
55.03%
100.00%

4,407
4,777

44.30%
44.97%
0.00%

10,518
792
77

55.41%
54.81%
53.47%

8,464
653
67

44.59%
45.19%
46.53%

11,236
23
128

55.27%
43.40%
67.37%

9,092
30
62

44.73%
56.60%
32.63%

6,999
4,388

69.93%
41.55%

3,010
6,174

30.07%
58.45%

3,045
2,169
412
287
834
5,384

54.01%
56.75%
58.69%
46.67%
58.12%
57.05%

2,593
1,653
290
328
601
4,053

45.99%
43.25%
41.31%
53.33%
41.88%
42.95%

3,107
3,097
5,183

56.60%
55.90%
54.32%

2,382
2,443
4,359

43.40%
44.10%
45.68%

58
642
6,538
96
310
3,743

51.33%
47.87%
57.55%
46.15%
42.35%
54.91%

55
699
4,823
112
422
3,073

48.67%
52.13%
42.45%
53.85%
57.65%
45.09%

9,475
1,912

53.56%
66.41%

8,217
967

46.44%
33.59%
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Survival Interval
1 year
2 years
3 years
4 years
5 years
More than 5 years
Year of diagnosis
2003 – 2009
2010 - 2016
Survival Interval 2nd Primary
1 year
2 years
3 years
4 years
5 years
More than 5 years
No second primary

1,452
1,197
1,171
1,170
1,033
5,364

33.56%
42.28%
51.63%
59.33%
63.03%
71.19%

2,874
1,634
1,097
802
606
2,171

66.44%
57.72%
48.37%
40.67%
36.97%
28.81%

5,701
5,686

56.89%
53.90%

4,320
4,864

43.11%
46.10%

850
234
179
136
105
408
9,475

59.15%
73.35%
71.60%
70.47%
73.94%
75.84%
53.56%

587
85
71
57
37
130
8,217

40.85%
26.65%
28.40%
29.53%
26.06%
24.16%
46.44%

Results
The demographic, clinical, and survival characteristics stratified by stage for included and
excluded subjects is presented in Table 1-2. The main differences between the included and excluded
cases were that the excluded cases had a higher percentage of patients from the Appalachian region
(41.29% compared to 27.41%) and excluded cases had a higher percentage of cases in the 0-12
month survival interval (34.15% compared 23.01%). The remaining variables were similar, except for
the morbidity variables, having 79.05% of the excluded cases missing morbidity status, comparison
would not be recommended. For those only missing stage, the individual morbidity groups were at
least 40% lowers in all categories, CHF, diabetes, hypertension, renal failure, and liver disease
compared to the included cases.
The demographic, clinical, and survival characteristics stratified by stage for included subjects
only is summarized in Table 1-3. Early-stage CRC makes up 55.4% of the total and the remaining
44.6% were late-stage cases. Comparing the demographic distribution of CRC range differences
within 10% of expected distribution will not be noted. Late-stage CRC patients had a higher
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percentage of younger patients (age groups 18-34 and 35-44 years), Hispanic patients, death, liver
disease, higher percentage of patients surviving less than 24 months, and higher percentage primary
payer sources of Medicaid, Military/other, and uninsured. Late-stage patients tended to have a lower
percentage of second primary malignancies, primary survival beyond 48 months, and secondary
survival beyond 12 months.
Bivariate models using the Elixhauser index predicting late-stage cancer by individual and
grouped comorbidities are in Table 1-4. Individual comorbidities found to be statistically significant
were CHF, hypertension, chronic pulmonary disease, liver disease, hypothyroidism, coagulopathy,
blood loss anemia, deficiency anemia, depression, weight loss, and electrolyte disorders. Some
comorbidities increased the odds of late-stage disease, e.g. liver disease (OR=1.432, 96% CI = 1.220 –
1.682), while others decreased the odds, e.g., hypertension (OR= 0.881, 95% CI = 0.883 – 0.931).
Grouped comorbidities found to be statistically significant were cardiovascular system, respiratory
system, gastrointestinal system, endocrine system, blood system, and having two or more individual
comorbidities. Bivariate models predicting death by individual and grouped comorbidities are in Table
1-5. All but five individual comorbidities (excluding hypertension, peptic ulcer disease,
hypothyroidism, drug abuse, and depression) and all but one comorbidity group (psychiatric) were
found to be statistically significant below the alpha level of 0.05 and the corresponding 95%
confidence limits did not include one.
There were three sets of three Cox proportional hazard models fitted, for a total of nine
models. These models were progressive comparisons of comorbidities from an individual level, to a
grouped body system level, and then an aggregate count of comorbidities. Some variables from the
individual level were not able to be grouped with other individual comorbidities and were therefore
transferred into the grouped model as their own group.
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Cox proportional hazard models of all-cause mortality can be found in Table 1-6 and includes
20,270 CRC patients from Kentucky diagnosed 2003-2016; there are three models viewing
comorbidity through an individual, system, or aggregate count lens.
Model 1 includes Individual comorbidities and patient factors. Due to the large number of
significant findings, we will group the statistically significant results in order from largest to smallest
effect. The individual comorbidities and patient factors that increased the hazard of all-cause
mortality by greater than 40% that were found to be significant were late-stage (HR= 3.198, 95%CI
3.046-3.357), aids (HR= 2.901, 95% CI 1.926-4.373), being 65 years or older (HR= 1.746, 95%CI 1.4212.143), primary payer sources of uninsured (HR= 1.711, 95%CI 1.538-1.903) or Medicaid (HR= 1.617,
95% CI 1.481-1.767), renal failure (HR= 1.570, 95%CI 1.432-1.720), CHF (HR=1.566, 95%CI 1.4671.672), weight loss (HR= 1.540, 95%CI 1.427-1.662 ), other neurological disorders excluding paralysis
(HR= 1.487, 95%CI 1.358-1.627), and coagulopathy (HR= 1.426, 95%CI 1.213-1.676 ). The individual
comorbidities and patient factors that increased the hazard of all-cause mortality by greater than 20%
but less than 40% that were found to be significant were pulmonary circulation disorders (HR= 1.394,
95%CI 1.204-1.615), electrolyte disorders (HR= 1.353, 95%CI 1.280-1.430 ), paralysis (HR= 1.347,
95%CI 1.087-1.671 ), primary payer source of Medicare (HR= 1.338, 95%CI 1.249-1.434 ) and
Military/other (HR= 1.317, 95%CI 1.076-1.612 ), chronic obstructive pulmonary disorder (HR= 1.290,
95%CI 1.224-1.359), liver disease (HR= 1.226, 95%CI 1.105-1.360), rheumatoid arthritis (HR= 1.223,
95%CI 1.023-1.462), and alcohol abuse (HR= 1.202, 95%CI 1.031-1.401). The individual comorbidities
and patient factors that increased the hazard of all-cause mortality by up to 20% that were found to
be significant were peripheral vascular disease (HR= 1.157, 95%CI 1.044-1.281), deficiency anemia
(HR= 1.146, 95%CI 1.086-1.210), being African American race (HR= 1.131, 95%CI 1.050-1.219),
Appalachian (HR= 1.112, 95%CI 1.064-1.163), being male (HR= 1.074, 95%CI 1.032-1.118), and having
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diabetes (HR= 1.068, 95%CI 1.015-1.123). The individual comorbidities and patient factors that were
protective and decreased the hazard of all-cause mortality by up to 20% were hypertension (HR=
0.929, 95%CI 0.892-0.968), having a second primary malignancy (HR= 0.928, 95%CI 0.879-0.980),
obesity (HR= 0.891, 95%CI 0.808-0.984), and blood loss anemia (HR= 0.872, 95%CI 0.788-0.964). The
individual comorbidities and patient factors that were protective and decreased the hazard of allcause mortality between 20% but less than 40% were being an other race compared to white (HR=
0.698, 95%CI 0.496-0.983) and receiving radiation therapy only (HR= 0.694, 95%CI 0.551-0.874). The
individual comorbidities and patient factors that were protective and decreased the hazard of allcause mortality by more than 40% were all treatments, in order of least to greatest, chemotherapy
only (HR= 0.520, 95%CI 0.467-0.580), chemotherapy and radiation (HR= 0.362, 95%CI 0.318-0.411),
surgery on the primary site only (HR= 0.183, 95%CI 0.169-0.198), and the largest reduction in hazards
with the treatment combination of surgery with radiation and/or chemotherapy (HR= 0.118, 95%CI
0.108-0.128).
Model 2 includes grouped comorbidities and patient factors. Again, due to the large number
of significant findings, statistically significant results will be grouped in order from largest to smallest
effect. The individual comorbidities and patient factors that increased the hazard of all-cause
mortality by greater than 40% that were found to be significant were late-stage (HR= 3.211, 95%CI ),
aids(HR= 3.083, 95%CI 2.046-4.645), being 65 or older (HR= 1.743, 95%CI 1.420-2.140), being
uninsured (HR= 1.728, 95%CI 1.554-1.921), having renal failure (HR= 1.685, 95%CI 1.539-1.845),
having Medicaid insurance (HR= 1.619, 95%CI 1.482-1.768), weight loss (HR= 1.542, 95%CI 1.4291.664), and other neurological disease excluding paralysis (HR= 1.536, 95%CI 1.411-1.672). The
individual comorbidities and patient factors that increased the hazard of all-cause mortality by
greater than 20% but less than 40% that were found to be significant were electrolyte disorders (HR=
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1.389, 95%CI 1.315-1.468), respiratory system disorders (HR= 1.373, 95%CI 1.306-1.444), having
Medicare (HR= 1.341, 95%CI 1.251-1.436) Military/other insurance (HR= 1.337, 95%CI 1.093-1.636),
and a substance abuse (HR= 1.202, 95%CI 1.050-1.376). The individual comorbidities and patient
factors that increased the hazard of all-cause mortality by up to 20% that were found to be significant
were gastrointestinal system disorders (HR= 1.160, 95%CI 1.1.057-1.274), blood system disorders
(HR= 1.139, 95%CI 1.086-1.195), being of black race (HR= 1.123, 95%CI 1.042-1.210), Appalachian
(HR= 1.100, 95%CI 1.052-1.150), and being male (HR= 1.083, 95%CI 1.041-1.126). The individual
comorbidities and patient factors that were protective and decreased the hazard of all-cause
mortality 20% were secondary primary malignancy (HR= 0.921, 95%CI 0.873-0.972), psychiatric
disorders (HR= 0.915, 95%CI 0.939-0.998), and obesity (HR= 0.896, 95%CI 0.812-0.989). The individual
comorbidities and patient factors that were protective and decreased the hazard of all-cause
mortality between 20% but less than 40% were treatment of radiation only (HR= 0.696, 95%CI 0.5530.877) and being an other race compared to white (HR= 0.681, 95%CI 0.483-0.959). The individual
comorbidities and patient factors that were protective and decreased the hazard of all-cause
mortality by more than 40% were all treatments, in order of least to greatest, chemotherapy only
(HR= 0.513, 95%CI 0.460-0.571), chemotherapy and radiation (HR= 0.354, 95%CI 0.312-0.402),
surgery on the primary site only (HR= 0.183, 95%CI 0.169-0.198), and the largest reduction in hazards
with the treatment combination of surgery with radiation and/or chemotherapy (HR= 0.114, 95%CI
0.105-0.124).
Model 3 includes aggregate count of comorbidities and patient factors. Like the previous
models, statistically significant results will be grouped in order from largest to smallest effect. The
individual comorbidities and patient factors that increased the hazard of all-cause mortality by
greater than 40% that were found to be significant were late-stage (HR= 3.271, 95%CI 3.116-3.434),
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being uninsured (HR= 1.773, 95%CI 1.595-1.970), having Medicaid (HR= 1.694, 95%CI 1.552-1.846),
being over the age of 65 (HR= 1.586, 95%CI 1.294-1.943), and having two or more comorbidities (HR=
1.495, 95%CI 1.421-1.572). The individual patient factor that increased the hazard of all-cause
mortality by greater than 20% but less than 40% that were found to be significant were having a
primary payer source of Medicare (HR= 1.388, 95%CI 1.296-1.486) and Military/other (HR= 1.286,
95%CI 1.051-1.573). The individual comorbidities and patient factors that increased the hazard of allcause mortality by up to 20% that were found to be significant were being black compared to white
(HR= 1.134, 95%CI 1.053-1.222), having one comorbidity (HR= 1.108, 95%CI 1.047-1.173), being male
(HR= 1.099, 95%CI 1.058-1.143), and Appalachian (HR= 1.052, 95%CI 1.007-1.099). The factor that
was protective and decreased the hazard of all-cause mortality 20% were having a secondary primary
malignancy (HR= 0.930, 95%CI 0.881-0.981). The individual patient factors that were protective and
decreased the hazard of all-cause mortality between 20% but less than 40% were treatment of
radiation only (HR= 0.738, 95%CI 0.587-0.929) and being of an other race compared to white (HR=
0.631, 95%CI 0.448-0.889). The individual comorbidities and patient factors that were protective and
decreased the hazard of all-cause mortality by more than 40% were again all treatments, in the same
order, chemotherapy only (HR= 0.486, 95%CI 0.436-0.541), chemotherapy and radiation (HR= 0.322,
95%CI 0.284-0.365), surgery on the primary site only (HR= 0.173, 95%CI 0.160-0.187), and the largest
reduction in hazards with the treatment combination of surgery with radiation and/or chemotherapy
(HR= 0.106, 95%CI 0.098-0.115).
Cox proportional hazard models of CRC mortality can be found in Table 1-7 and includes 9,866
CRC patients from Kentucky diagnosed 2003-2016, there are three models viewing comorbidity
through an individual, system, or aggregate count lens.
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Model 1 includes Individual comorbidities and patient factors. The individual comorbidities
and patient factors that increased the hazard of CRC mortality were renal failure (HR= 1.809, 95% CI
1.597-2.05), pulmonary circulation disorders (HR= 1.419, 95% CI 1.148-1.755), CHF (HR= 1.390, 95% CI
1.27-1.521), weight loss (HR= 1.327,95% CI 1.159-1.519), other neurological diseases excluding
paralysis (HR=1.308, 95% CI 1.148-1.49), Medicaid (HR=1.300, 95% CI 1.106-1.529), coagulopathy
(HR= 1.300, 95% CI 1.02-1.655), chronic obstructive pulmonary disorder (HR= 1.225, 95% CI 1.1361.321), Medicare (HR= 1.215, 95% CI 1.087-1.357), electrolyte disorders (HR= 1.182, 95% CI 1.0851.288), being male (HR= 1.120, 95% CI 1.052-1.193), deficiency anemia (HR= 1.099, 95% CI 1.011.196), and diabetes (HR= 1.097, 95% CI 1.017-1.184). The individual comorbidities and patient
factors that were protective and decreased the hazard of CRC-specific mortality were having a second
primary malignancy (HR= 0.867, 95% CI 0.805-0.933), blood loss anemia (HR= 0.807, 95% CI 0.6940.938), treatment of radiation only (HR= 0.488, 95% CI 0.294-0.81), chemotherapy and radiation (HR=
0.367, 95% CI 0.285 - 0.473) surgery on primary site only (HR= 0.340, 95% CI 0.296-0.39),
chemotherapy only (HR= 0.242, 95% CI 0.184-0.318), and surgery with radiation and/or
chemotherapy (HR= 0.179, 95% CI 0.154-0.207).
Model 2 includes grouped comorbidities and patient factors. The individual comorbidities and
patient factors that increased the hazard of CRC mortality were renal failure (HR= 1.949, 95% CI
1.725-2.204), neurological system (HR= 1.386, 95% CI 1.229-1.563), weight loss (HR= 1.344, 95% CI
1.174-1.539), having Medicaid (HR= 1.301, 95% CI 1.107-1.529), respiratory system (HR= 1.286, 95%
CI 1.196-1.383), having Medicare (HR= 1.218, 95% CI 1.091-1.361), electrolyte disorders (HR= 1.199,
95% CI 1.101-1.305), gastrointestinal system (HR= 1.186, 95% CI 1.019-1.381), being male (HR= 1.115,
95% CI 1.049-1.187), cardiovascular disease (HR= 1.093, 95% CI 1.024-1.166), and endocrine system
(HR= 1.088, 95% CI 1.013-1.168). The individual comorbidities and patient factors that were
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protective and decreased the hazard of CRC-specific mortality were having a secondary primary
malignancy (HR= 0.868, 95% CI 0.807-0.935), radiation therapy only (HR= 0.483, 95% CI 0.291-0.802),
chemotherapy and radiation therapies (HR= 0.365, 95% CI 0.283-0.471), surgery on primary site only
(HR= 0.339, 95% CI 0.296-0.389), chemotherapy only (HR= 0.241, 95% CI 0.183-0.316), and surgery
with radiation and/or chemotherapy (HR= 0.177, 95% CI 0.152-0.205).
Model 3 includes an aggregate count of comorbidities and other patient factors. The other
covariates that increased the hazard of CRC mortality include Medicaid (HR=1.334, 95% CI 1.1351.567), Medicare (HR = 1.242, 95% CI 1.112-1.388), and male gender (HR = 1.142, 95% CI 1.0751.214). The individual comorbidities and patient factors that were protective and decreased the
hazard of CRC mortality were having a secondary primary malignancy(HR = 0.855, 95% CI 0.794-0.92),
radiation therapy only (HR = 0.495, 95% CI 0.298-0.822), chemotherapy and radiation (HR = 0.341,
95% 0.265-0.439), surgery on primary site only (HR = 0.329, 95% CI 0.287-0.378), chemotherapy only
(HR = 0.228, 95% CI 0.174-0.300), and surgery with radiation and/or chemotherapy (HR = 0.168, 95%
CI 0.145-0.195).
Cox proportional hazard models of second primary malignancy can be found in Table 1-8 and
includes 2,624 CRC patients from Kentucky diagnosed 2003-2016, there are three models viewing
comorbidity through an individual, system, or aggregate count lens.
Model 1 includes Individual comorbidities and patient factors. The individual comorbidities
and patient factors that increased the hazard of secondary primary malignancy were renal failure
(HR= 1.856, 95% CI 1.428-2.412), being uninsured (HR= 1.786, 95% CI 1.304-2.445), late-stage (HR=
1.723, 95% CI 1.512-1.963), CHF (HR= 1.670, 95% CI 1.393-2.002), Medicaid (HR= 1.522, 95% CI 1.1432.027), Medicare (HR= 1.427, 95% CI 1.181-1.724), weight loss (HR= 1.319, 95% CI 1.033-1.684),
deficiency anemia (HR= 1.236, 95% CI 1.072-1.426), chronic obstructive pulmonary disorder (HR=
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1.235, 95% CI 1.079-1.415), electrolyte disorders (HR= 1.173, 95% CI 1.006-1.369), being male (HR=
1.159, 95% CI 1.041-1.29), and Appalachian (HR= 1.129, 95% CI 1.001-1.275). The individual
comorbidities and patient factors that were protective and decreased the hazard of secondary
primary malignancy were surgery on primary site only (HR= 0.568, 95% CI 0.375-0.859) and surgery
with radiation and/or chemotherapy (HR= 0.477, 95% CI 0.312-0.728).
Model 2 includes grouped comorbidities and patient factors. The individual comorbidities and
patient factors that increased the hazard of secondary primary malignancy were aids (HR= 3.310, 95%
CI 1.058-10.36), renal failure (HR= 1.976, 95% CI 1.529-2.552), being uninsured (HR= 1.798, 95% CI
1.314-2.460), late-stage (HR= 1.719, 95% CI 1.508-1.96), substance abuse (HR= 1.543, 95% CI 1.0832.198), Medicaid (HR= 1.488, 95% CI 1.118-1.980), Medicare (HR= 1.444, 95% CI 1.195-1.745), weight
loss (HR= 1.296, 95% CI 1.015-1.654), respiratory system (HR= 1.285, 95% CI 1.127-1.466), electrolyte
disorders (HR= 1.218, 95% CI 1.046-1.420), blood system (HR= 1.198, 95% CI 1.057-1.358), and being
male (HR= 1.154, 95% CI 1.039-1.281). The individual comorbidities and patient factors that were
protective and decreased the hazard of secondary primary malignancy were surgery on primary site
only (HR= 0.542, 95% CI 0.359-0.819) and surgery with radiation and/or chemotherapy (HR= 0.446,
95% CI 0.293-0.680).
Model 3 includes an aggregate count comorbidities and patient factors. The individual
comorbidities and patient factors that increased the hazard of secondary primary malignancy were
being uninsured (HR= 1.866, 95% CI 1.367-2.546), late-stage (HR= 1.713, 95% CI 1.504-1.952),
Medicaid (HR= 1.595, 95% CI 1.205-2.113), Medicare (HR= 1.504, 95% CI 1.247-1.813), having two or
more comorbidities (HR= 1.400, 95% CI 1.226- 1.599), and being male (HR= 1.175, 95% CI 1.0591.303).The individual comorbidities and patient factors that were protective and decreased the
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hazard of secondary primary malignancy were surgery on primary site only (HR= 0.543, 95% CI 0.3610.818) and surgery with radiation and/or chemotherapy (HR= 0.443, 95% CI 0.291-0.673).
Kaplan Meier Survival Curves (Censoring and LifeTest) that compare early to late-stage
survival of diagnosed primary CRC cases in Kentucky can be found in Figure 1-2. Early-stage failed
cases (those that died during the interval) were 4,388 and 61.46% were censored (6,999). Late-stage
failed cases were 6,174 and 32.77% (3,010) were censored. The rank tests for homogeneity indicate a
significant difference between survival of late and early-stage initial primary CRC. The p values of the
log-rank test and Wilcoxon test were both <0.001. The height of the drop in the first 24 months is
very steep for late-stage below 60% CRC patients compared to early-stage that dropped just below
90%, there were more late-stage patients at risk of failing. At the end of the time period, early-stage
survival probability is around 60% and late-stage is at 30%. We do not see a steep drop at the end of
either curve and there is no interaction between the two curves.
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Table 1-4. Elixhauser and Comorbidity Grouping Bivariate (Outcome Late-stage)
Variable

Individual Morbidities
OR

Upper
95% CI
0.795

Lower
95% CI
0.988

Grouped
Variable

CHF

0.886*

Valvular Disorder

0.864

0.713

1.048

Peripheral
Vascular Disease
Hypertension

0.873

0.740

1.030

0.881***

0.833

0.931

Pulmonary
Circulation
Chronic
Pulmonary
Liver Disease

1.047

0.823

1.331

0.897**

0.828

0.971

1.432***

1.220

1.682

Peptic ulcer

1.228

0.897

1.681

Paralysis

1.033

0.709

1.506

Other
Neurological
Disease
Diabetes

0.971

0.836

1.128

Neurological
System

0.933

0.869

1.001

Hypothyroid

0.874*

0.774

0.987

Coagulopathy

1.317*

1.002

1.731

Blood loss Anemia

1.230**

1.065

1.421

Deficiency Anemia

1.362***

1.266

1.464

Alcohol Abuse

1.176

0.930

1.486

Drug Abuse

0.978

0.649

1.473

Psychosis

1.281

0.969

1.694

Depression

1.170*

1.027

1.333

Renal Failure

0.869

0.745

1.012

Aids

1.436

0.683

3.019

Obesity

0.920

0.812

1.043

Rheumatoid
Arthritis
Weight loss

1.037

0.791

1.360

1.856***

1.636

2.107

Electrolyte

1.381***

1.267

1.504

OR

Upper
95% CI

Lower
95% CI

0.880***

0.833

0.930

0.918*

0.849

0.993

1.386***

1.200

1.601

0.990

0.860

1.141

Endocrine
System

0.914**

0.855

0.976

Blood System

1.369***

1.274

1.471

Substance
Abuse

1.138

0.923

1.402

Psychiatric

1.178**

1.043

1.330

Cardiovascular
System

Respiratory
System
Gastrointestinal
System

Total Number of Comorbidity Groups
0
1
2+

* p < 0.05 ; ** p < 0.01 ; *** p < 0.0001

Grouped Morbidities

ref
1.029
1.097**

0.954
1.026

1.109
1.173
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Table 1-5. Elixhauser and Comorbidity Grouping Bivariate (Outcome Death)
Variable

Individual Morbidities
OR

Grouped Morbidities

CHF

3.914***

Upper
95% CI
3.435

Valvular Disorder

1.679***

1.378

2.045

Peripheral Vascular
Disease
Hypertension

1.945***

1.636

2.312

1.029

0.974

1.087

Pulmonary Circulation

2.502***

1.915

3.269

Chronic Pulmonary

1.874***

1.728

2.033

Liver Disease

1.620***

1.372

1.912

Peptic ulcer

1.309

0.953

1.800

Paralysis

3.415***

2.171

5.374

Other Neurological
Disease
Diabetes

2.532***

2.146

2.988

Neurological
System

1.179***

1.099

1.265

Hypothyroid

0.896

0.795

1.011

Endocrine
System

1.121**

1.049

1.196

Coagulopathy

2.798***

2.046

3.826

Blood loss Anemia

1.872***

1.608

2.179

Blood System

1.720***

1.599

1.851

Deficiency Anemia

1.670***

1.550

1.799

Alcohol Abuse

1.554**

1.221

1.977

Drug Abuse

1.374

0.908

2.079

Substance
Abuse

1.631***

1.314

2.024

Psychosis

1.680**

1.256

2.246

Depression

0.886

0.778

1.010

Psychiatric

0.965

0.855

1.090

Renal Failure

2.974***

2.500

3.538

Aids

4.366**

1.659

11.489

Obesity

0.636***

0.560

0.721

Rheumatoid Arthritis

1.404*

1.067

1.849

Weight loss

2.867***

2.489

3.303

Electrolyte

2.289***

2.088

2.508

* p < 0.05 ; ** p < 0.01 ; *** p < 0.0001

Lower
95% CI
4.459

Grouped
Variable

Upper
95% CI

Lower
95% CI

1.262***

1.194

1.333

Respiratory
System

1.899***

1.752

2.058

Gastrointestinal
System

1.553***

1.339

1.801

2.648***

2.261

3.101

Cardiovascular
System

Total Number of Comorbidity Groups
0
1
2+

OR

ref
1.212***
2.064***

1.124
1.929

1.307
2.208
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Table 1-6. Cox Proportional Hazard models of All-cause mortality, 20,270 CRC patients 2003-2016
Variable
Cardiovascular Disease
CHF
Valvular Disorder
Peripheral Vascular Disease
Hypertension
Respiratory System
Pulmonary Circulation
Chronic Pulmonary
Gastrointestinal
Liver Disease
Peptic ulcer
Neurological System
Paralysis
Other Neurological Disease
Endocrine System
Diabetes
Hypothyroid
Blood System
Coagulopathy
Blood loss Anemia
Deficiency Anemia
Substance Abuse
Alcohol Abuse
Drug Abuse
Psychiatric
Psychosis
Depression
Renal Failure
Aids
Obesity
Rheumatoid Arthritis
Weight loss
Electrolyte
Total Comorbidity
0 (ref)
1
2+
Stage of Cancer (late vs early)
Second primary(yes/no)
Sex (Female Ref)
Race (black vs white)
Race (other vs white)
Age or age group
18 – 34 years (ref)
35 – 44 years

HR

Model 1
CI
CI
low
High

1.566***

1.467

1.672

1.047

0.927

1.183

1.157**

1.044

1.281

0.929**

0.892

0.968

1.394***

1.204

1.615

1.290***

1.224

1.359

1.226**

1.105

1.360

0.910

0.739

1.121

1.347**

1.087

1.671

1.487***

1.358

1.627

1.068*

1.015

1.123

0.918

0.841

1.002

1.426***

1.213

1.676

0.872**

0.788

0.964

1.146***

1.086

1.210

1.202*

1.031

1.401

1.067

0.811

1.404

HR

Model 2
CI
CI
low
High

1.033

0.992

1.077

1.373***

1.306

1.444

1.160**

1.057

1.274

1.536***

1.411

1.672

1.019

0.972

1.068

1.139***

1.086

1.195

1.202**

1.050

1.376

0.915**

0.839

0.998

1.045

0.875

1.248

0.937

0.852

1.030

1.570***

1.432

1.720

1.685***

1.539

1.845

2.902***

1.926

4.373

3.083***

2.046

4.645

0.891*

0.808

0.984

0.896**

0.812

0.989

1.223*

1.023

1.462

1.179

0.986

1.409

1.540***

1.427

1.662

1.542***

1.429

1.664

1.353***

1.280

1.430

1.389***

1.315

1.468

HR

Model 3
CI
CI
low
High

ref

ref

ref

1.108**

1.047

1.173

1.495***

1.421

1.572

3.198***

3.046

3.357

3.211***

3.058

3.371

3.271***

3.116

3.434

0.928**

0.879

0.980

0.921**

0.873

0.972

0.930**

0.881

0.981

1.074**

1.032

1.118

1.083***

1.041

1.126

1.099***

1.058

1.143

1.131**

1.050

1.219

1.123**

1.042

1.210

1.134**

1.053

1.222

0.698*

0.496

0.983

0.681**

0.483

0.959

0.631**

0.448

0.889

ref

ref

ref

ref

ref

ref

ref

ref

ref

0.975

0.780

1.218

0.977

0.782

1.220

0.905

0.725

1.128
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45 – 54 years
0.991
55 – 64 years
1.166
65 + years
1.746***
Source of payment
ref
Private Payer (ref)
Medicaid
1.617***
Medicare
1.338***
Military/Other
1.317**
Uninsured
1.711***
Appalachian
1.112***
Treatment
ref
No Treatment (ref)
Chemotherapy Only
0.520***
Radiation Only
0.694**
Surgery on Primary Site Only 0.183***
Chemotherapy and Radiation 0.362***
Surgery with Radiation
and/or Chemotherapy
0.118***
* p < 0.05 ; ** p < 0.01 ; *** p < 0.0001

0.809

1.216

0.982

0.801

1.204

0.911

0.745

1.115

0.954

1.425

1.152

0.943

1.408

1.054

0.864

1.286

1.421

2.143

1.743***

1.420

2.140

1.586***

1.294

1.943

ref

ref

ref

ref

ref

ref

ref

ref

1.481

1.767

1.619***

1.482

1.768

1.694***

1.552

1.849

1.249

1.434

1.341***

1.251

1.436

1.388***

1.296

1.486

1.076

1.612

1.337**

1.093

1.636

1.286*

1.051

1.573

1.538

1.903

1.728***

1.554

1.921

1.773***

1.595

1.970

1.064

1.163

1.100***

1.052

1.150

1.052*

1.007

1.099

ref

ref

ref

ref

ref

ref

ref

ref

0.467

0.580

0.513***

0.460

0.571

0.486***

0.436

0.541

0.551

0.874

0.696**

0.553

0.877

0.738**

0.587

0.929

0.169

0.198

0.183***

0.169

0.198

0.173***

0.160

0.187

0.318

0.411

0.354***

0.312

0.402

0.322***

0.284

0.365

0.108

0.128

0.114***

0.105

0.124

0.106***

0.098

0.115
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Table 1-7. Cox Proportional Hazard models of CRC mortality, 9,866 CRC patients 2003-2016
Variable
Cardiovascular Disease
CHF
Valvular Disorder
Peripheral Vascular Disease
Hypertension
Respiratory System
Pulmonary Circulation
Chronic Pulmonary
Gastrointestinal
Liver Disease
Peptic ulcer
Neurological System
Paralysis
Other Neurological Disease
Endocrine System
Diabetes
Hypothyroid
Blood System
Coagulopathy
Blood loss Anemia
Deficiency Anemia
Substance Abuse
Alcohol Abuse
Drug Abuse
Psychiatric
Psychosis
Depression
Renal Failure
Aids
Obesity
Rheumatoid Arthritis
Weight loss
Electrolyte
Total Comorbidity
0 (ref)
1
2+
Stage of Cancer (late vs early)
Second primary(yes/no)
Sex (Male vs Female)
Race (black vs white)
Race (other vs white)
Age or age group
18 – 34 years (ref)
35 – 44 years

HR

Model 1
CI
CI
low
High

1.390***

1.270

1.521

1.045

0.880

1.241

1.070

0.928

1.233

1.011

0.949

1.077

1.419**

1.148

1.755

1.225***

1.136

1.321

1.177

0.989

1.401

1.154

0.846

1.572

1.190

0.887

1.596

1.308***

1.148

1.490

1.097*

1.017

1.184

1.107

0.973

1.259

1.300*

1.020

1.655

0.807**

0.694

0.938

1.099*

1.010

1.196

1.059

0.834

1.343

0.986

0.659

1.476

HR

Model 2
CI
CI
low High

1.093**

1.024

1.166

1.286***

1.196

1.383

1.186*

1.019

1.381

1.386***

1.229

1.563

1.088*

1.013

1.168

1.061

0.986

1.142

1.056

0.859

1.298

1.061

0.927

1.214

1.108

0.864

1.420

1.091

0.937

1.269

1.809***

1.597

2.050

1.949***

1.725

2.204

1.171

0.584

2.349

1.176

0.586

2.357

1.074

0.918

1.255

1.077

0.922

1.259

1.211

0.946

1.552

1.189

0.929

1.522

1.327***

1.159

1.519

1.344***

1.174

1.539

1.182**

1.085

1.288

1.199***

1.101

1.305

HR

Model 3
CI
low

ref

ref

ref

1.118*

1.015

1.232

CI
High

1.504***

1.384

1.634

1.074

0.994

1.160

1.067

0.988

1.152

1.063

0.985

1.148

0.867**

0.805

0.933

0.868**

0.807

0.935

0.855***

0.794

0.920

1.120**

1.052

1.193

1.115**

1.049

1.187

1.142***

1.075

1.214

1.083

0.959

1.223

1.062

0.941

1.199

1.072

0.950

1.209

1.004

0.501

2.014

0.949

0.474

1.903

0.920

0.459

1.843

ref

ref

ref

ref

ref

ref

ref

ref

ref

0.829

0.437

1.573

0.836

0.441

1.585

0.821

0.433

1.557
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45 – 54 years
1.001
55 – 64 years
1.274
65 + years
1.496
Source of payment
ref
Private Payer (ref)
Medicaid
1.300**
Medicare
1.215**
Military/Other
0.990
Uninsured
1.179
Appalachian
1.016
Treatment
ref
No Treatment (ref)
Chemotherapy Only
0.242***
Radiation Only
0.488**
Surgery on Primary Site Only 0.340***
Chemotherapy and Radiation 0.367***
Surgery with Radiation
and/or Chemotherapy
0.179***
* p < 0.05 ; ** p < 0.01 ; *** p < 0.0001

0.559

1.793

0.986

0.551

1.765

0.978

0.546

1.750

0.717

2.264

1.261

0.710

2.241

1.229

0.692

2.183

0.839

2.668

1.499

0.841

2.672

1.470

0.825

2.619

ref

ref

ref

ref

ref

ref

ref

ref

1.106

1.529

1.301**

1.107

1.529

1.334**

1.135

1.567

1.087

1.357

1.218**

1.091

1.361

1.242**

1.112

1.388

0.645

1.519

0.979

0.638

1.502

0.978

0.638

1.501

0.935

1.488

1.174

0.930

1.481

1.180

0.935

1.488

0.946

1.091

1.002

0.934

1.076

0.990

0.923

1.061

ref

ref

ref

ref

ref

ref

ref

ref

0.184

0.318

0.241***

0.183

0.316

0.228***

0.174

0.300

0.294

0.810

0.483**

0.291

0.802

0.495**

0.298

0.822

0.296

0.390

0.339***

0.296

0.389

0.329***

0.287

0.378

0.285

0.473

0.365***

0.283

0.471

0.341***

0.265

0.439

0.154

0.207

0.177***

0.152

0.205

0.168***

0.145

0.195
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Table 1-8. Cox Proportional Hazard models of Second Primary Cancer, 2,624 CRC patients 2003-2016
Variable
Cardiovascular Disease
CHF
Valvular Disorder
Peripheral Vascular Disease
Hypertension
Respiratory System
Pulmonary Circulation
Chronic Pulmonary
Gastrointestinal
Liver Disease
Peptic ulcer
Neurological System
Paralysis
Other Neurological Disease
Endocrine System
Diabetes
Hypothyroid
Blood System
Coagulopathy
Blood loss Anemia
Deficiency Anemia
Substance Abuse
Alcohol Abuse
Drug Abuse
Psychiatric
Psychosis
Depression
Renal Failure
Aids
Obesity
Rheumatoid Arthritis
Weight loss
Electrolyte
Total Comorbidity
0 (ref)
1
2+
Stage of Cancer (late vs early)
Sex (Male vs Female)
Race (black vs white)
Race (other vs white)
Age or age group
18 – 34 years (ref)
35 – 44 years

HR

Model 1
CI
low

CI
High

1.670***

1.393

2.002

1.110

0.784

1.572

1.010

0.747

1.365

0.981

0.879

1.095

1.299

0.806

2.095

1.235**

1.079

1.415

1.211

0.902

1.626

1.308

0.804

2.130

1.338

0.710

2.519

1.150

0.870

1.520

1.082

0.944

1.239

0.953

0.747

1.217

0.950

0.576

1.568

0.921

0.713

1.189

1.236**

1.072

1.426

1.550

1.069

2.247

1.114

0.330

3.754

Model 2
CI
low

CI
High

1.057

0.949

1.179

1.285**

1.127

1.466

1.258

0.977

1.621

1.237

0.959

1.595

1.033

0.910

1.173

1.198**

1.057

1.358

1.543*

1.083

2.198

0.887

0.675

1.167

HR

1.359

0.740

2.495

0.846

0.628

1.140

1.856***

1.428

2.412

1.976***

1.529

3.018

0.961

9.477

3.310*

1.058

2.552
10.36
0

0.971

0.755

1.248

0.992

0.775

1.270

0.841

0.544

1.299

0.818

0.530

1.263

1.319*

1.033

1.684

1.296*

1.015

1.654

1.173*

1.006

1.369

1.218*

1.046

1.420

HR

Model 3
CI
CI
low High

ref

ref

ref

1.106

0.951

1.285

1.400***

1.226

1.599

1.723***

1.512

1.963

1.719***

1.508

1.960

1.713***

1.504

1.952

1.159**

1.041

1.290

1.154**

1.039

1.281

1.175**

1.059

1.303

1.061

0.868

1.061

1.061

0.870

1.295

1.083

0.890

1.318

0.508

0.162

0.508

0.464

0.148

1.454

0.475

0.152

1.483

ref

ref

ref

ref

ref

ref

ref

ref

ref

0.757

0.292

1.961

0.758

0.293

1.962

0.753

0.292

1.946
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45 – 54 years
0.609
55 – 64 years
0.691
65 + years
1.027
Source of payment
ref
Private Payer (ref)
Medicaid
1.522**
Medicare
1.427**
Military/Other
1.907
Uninsured
1.786**
Appalachian
1.129*
Treatment
ref
No Treatment (ref)
Chemotherapy Only
1.494
Radiation Only
1.812
Surgery on Primary Site Only 0.568**
Chemotherapy and Radiation 1.124
Surgery with Radiation
and/or Chemotherapy
0.477**
* p < 0.05 ; ** p < 0.01 ; *** p < 0.0001

0.247

1.500

0.607

0.246

1.495

0.581

0.236

1.429

0.283

1.690

0.691

0.283

1.689

0.665

0.273

1.622

0.416

2.534

1.034

0.419

2.550

0.987

0.401

2.428

ref

ref

ref

ref

ref

ref

ref

ref

1.143

2.027

1.488**

1.118

1.980

1.595**

1.205

2.113

1.181

1.724

1.444**

1.195

1.745

1.504***

1.247

1.813

0.936

3.885

1.800

0.884

3.666

1.863

0.916

3.787

1.304

2.445

1.798**

1.314

2.460

1.866***

1.367

2.546

1.0001

1.275

1.121

0.994

1.265

1.068

0.949

1.202

ref

ref

ref

ref

ref

ref

ref

ref

0.857

2.604

1.507

0.865

2.624

1.591

0.916

2.765

0.503

6.526

1.436

0.427

4.835

1.602

0.481

5.334

0.375

0.859

0.542**

0.359

0.819

0.543**

0.361

0.818

0.614

2.058

1.046

0.572

1.912

0.975

0.535

1.775

0.312

0.728

0.446**

0.293

0.680

0.443**

0.291

0.673
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Figure 1-2. Kaplan Meier Survival Curves (Censoring and LifeTest) Comparing Early and Late Stage
Survival of Diagnosed Primary CRC Patients in Kentucky
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Discussion
Many of the variables across all nine models in the Cox proportional hazard models were
statistically significant; the all-cause mortality had the highest number of statistically significant
variables. The individual comorbidities tended to have a larger effect size compared to the grouped
system comorbidities and the overall comorbidity count, although some demographic/ patient factor
effects tended to slightly increase as we moved across the models.
In the all-cause mortality models, there were several personal factors that remained
significant across all three models. The biggest effect was seen in late-stage (M1: HR= 3.198, 95% CI
3.046-3.357, M2: HR= 3.211 95% CI, 3.058-3.371, M3: HR= 3.271, 95% CI 3.116-3.434). What this
means is that if a patient has late-stage CRC they have 3.198 / 3.211/ or 3.271 (corresponding to
model progress 1-2-3) times the hazard of dying compared to those patients that have early-stage
CRC. Others factors that remained significant and also had an increased hazard of all-cause mortality
across all three models were 65 and older, Appalachian, males, black, having Medicaid, Medicare,
Military/other, and uninsured compared to having a private payer insurance, weight loss, renal
failure, aids, paralysis, and other neurological disease excluding paralysis . There were also protective
findings. The smallest effect was seen in the treatment of surgery at primary site with radiation
and/or chemotherapy (M1: HR= 0.118, 95%CI 0.108-0.128, M2: HR= 0.114 95%CI 0.105-0.124, M3:
HR= 0.106 95%CI 0.098-0.115). What this means is that if a patient has the combination treatment of
surgery with radiation and/or chemotherapy they have only 10.8% / 10.5% / or 11.8% (corresponding
to model progress 1-2-3) of the hazard of dying compared to those patients that do not receive
treatment. This is an average reduction of about 88% in the hazard of dying. Other protective factors
that were seen across the model were hypertension, blood loss anemia, obesity, having a second
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primary, being other race compared to white, and all treatments (chemotherapy only, radiation only,
surgery at primary site only, chemotherapy and radiation, as well as the above mentioned surgery
with radiation and/or chemotherapy. It is interesting that any treatment reduced the hazards of allcause mortality by 30% - 88% compared to having no treatment. The all treatment combination
performed the best and radiation performed the worst, but all reduced the hazards of dying
compared to no treatment. Other comorbidities that were significant on the individual level, when
grouped lost their effect. For example, CHF (HR= 1.566, 95%CI 1.467-1.672), peripheral vascular
disease (HR= 1.157, 95%CI 1.044-1.281), and hypertension (HR= 0.929, 95%CI 0.892-0.968) were
combined with valvular disorder (not found to be significant) and the protective finding of
hypertension. The increased hazard of CHF and peripheral vascular disorder were washed out in the
cardiovascular disease grouped mortality, which was not significant. The same is true with the
endocrine system group where diabetes was individually significant and hypothyroidism was not, the
effect was lost in the group. Model 3, the aggregate count of comorbidity with the personal factors,
all variables were significant except one age group, 55-64 years old.
In the CRC mortality models, there were fewer comorbidities and clinical factors that were
significant and the effects were not as high as all-cause mortality. The biggest statistically significant
effect in CRC-cause mortality was in renal failure (M1: HR= 1.809, 95%CI 1.597-2.050), M2: HR= 1.949
95% CI 1.725-2.204)). This means is that if a patient has renal failure they have 1.809 or 1.949 times
the hazard of dying from CRC mortality compared to those patients that do not have renal failure.
Other factors that remained significant and also had an increased hazard of CRC mortality across all
three models were CHF only and the aggregated category cardiovascular disease, both pulmonary
circulation and chronic obstructive pulmonary disorders and the aggregated category respiratory
system, neurological disorders but not paralysis and the aggregated category neurological system,
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and diabetes only and the aggregated category endocrine system, weight loss, electrolyte disorders,
being male, and having Medicaid or Medicare compared to a private payer insurance. Both aggregate
counts of comorbidity were statistically significant, having one comorbidity increased the hazard of
dying by 11.8% and having two or more comorbidities increased the risk of dying by 50.4% compared
to those who have no comorbidities. There were also protective effects, the smallest of which, like
that of all-cause mortality was seen in the treatment of surgery at primary site with radiation and/or
chemotherapy (M1: HR= 0.179 95%CI 0.154-0.207, M2: HR= 0.177, 95%CI 0.152-0.205, M3: HR=
0.168 95%CI 0.145-0.195). This means is that if a patient has the treatment combination of surgery
with radiation and/or chemotherapy they have only 17.9% / 17.7% / or 16.8% of the hazard of dying
compared to those patients who do not receive any of the three treatment options in this study
(surgery, radiation, chemotherapy). This is an average reduction of about 82% in the hazard of dying.
Other protective factors that were seen across the models were blood loss anemia, having a second
primary, and like all-cause mortality, any treatment reduced the hazard of dying from CRC-specific
mortality. All treatments reduced the hazard by at least 51%, ranging up to 82.1% reduction in the
hazards by receiving some treatment compared to no treatment. What is interesting in this set of Cox
models is that some effects are not present in variables that we would have expected, those were
late-stage, age, Appalachian, and the uninsured.
In the second primary malignancy models, there were some personal factors and
comorbidities that were significant. The biggest effects were seen in renal failure (M1: HR= 1.856,
95%CI 1.428-2.412, M2: HR= 1.976, 95%CI 1.529-2.552) and late-stage CRC (M1: HR= 1.723, 95%CI
1.006-1.369, M2: HR= 1.719, 95%CI 1.508-1.960, M3: HR= 1.713 95%CI 1.504-1.952). This means that
if a patient has renal failure, they have 1.856 or 1.976 times the hazard of developing a second
primary malignancy compared to those who do not have renal failure. The same is true for late-stage
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CRC patients, they have 1.723 / 1.719/ or 1.713 times the hazard of having a secondary primary
malignancy compared to those patients who have early-stage CRC. The other factors that were
significant and had an increased hazard of all-cause mortality across all three models were CHF,
chronic obstructive pulmonary disorder up to the grouped respiratory system, deficiency anemia up
to the grouped blood system, substance use grouped only, weight loss, electrolyte disorders, being
male, having Medicaid, Medicare, or uninsured compared to private payer insurance, and having two
or more comorbidities compared to none. There were also protective findings. The smallest effect,
like that of all-cause mortality was seen in the treatment of surgery at primary site with radiation
and/or chemotherapy (M1: HR= 0.477, 95%CI 0.312-0.728, M2: HR= 0.446 95%CI 0.293-0.680, M3:
HR= 0.443 95%CI 0.291-0.673). If a patient has the treatment combination of surgery with radiation
and/or chemotherapy they have only 47.7% / 44.6% / or 44.3% of the hazard of dying compared to
those patients that do not receive treatment. The other protective factor that were seen across the
models was surgery at the primary site only reduced the hazard of dying from CRC-specific mortality.
The only protective factors were treatment that included some sort of surgery compared to no
treatment. It is also really interesting that we did not see any statistically significant findings in any of
the models of expected variables such as age groups, race, and any treatments that did not include
surgery. Surgery has been shown to produce long-term survival rates and can be performed safely
with low mortality.67, 68 Although the remaining treatments were non-significant, this was the only
regression where any treatment at all compared to no treatment didn’t reduce the hazards.
Chemotherapy, radiation, and the combination of both had a non-significant effect of increasing the
hazards of secondary primary malignancy. The National Cancer Institute has noted that cancer
treatments such as radiation and chemotherapy may increase the risk of second primary cancers,
other studies have also found that having any combination of these cancer treatments increase the
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likelihood of developing a second primary malignancy.69-71 While our results were not significant, it is
in line with previous research and helps validate the results that we are seeing in this study.
Comparing between the models, the mortality models seem to be much more similar to each
other than the secondary primary model. Late-stage increased the hazard of dying in both mortality
models and the secondary primary malignancy model, but was only significant in the all-cause
mortality model. Obesity decreased the hazard of all-cause mortality and secondary primary but
increased the hazard of CRC mortality. The individual comorbidities seemed to highlight the effect
better than the collapsed and aggregate comorbidity count; some significant relationships of
individual comorbidities were obscured through the process of aggregations.
The Kaplan Meier survival curves (Censoring and LifeTest) comparing early and late-stage
survival shows the vast difference between the two stages. The initial steep drop in the first 24
months in late-stage is below 60% survival in this population of CRC patients compared to early-stage
that dropped just below 90%. By 10 years, the late-stage survival was half of the early-stage survival
at about 60% survival for early-stage and about 30% for late-stage. The 2015 U.S. combined CRC
relative 5-year survival rates were 64% and 10-year was 58%3. Early-stage CRC has a 5-year survival
rate of 90% but it declines to 71% and 14% for late-stages.3 The curves in this study are consistent
with U.S. survival rates, further validating the results of the study.
Limitations
There are several limitations to this study. The first is potential selection bias, there were a
total of 28,229 patients identified by KCR that were diagnosed with initial primary CRC during the
study time period. After missing data exclusions, the final total was 20,571 patients, an exclusion of
7,658 or 23.1%% of the total identified patients. The missing comorbidities data could be due to the
reality that many reporting hospitals are not part of the Commission of Cancer (CoC), a group that
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requires comprehensive standardized data collection.19, 20 The second major limitation is the
potential for comorbidities to be under reported to the registry. Comorbidities in the dataset are
captured at the time of diagnosis. There is a potential that the reporting facility may not fully account
for any comorbidities diagnosed prior to the primary CRC diagnosis. Starfield et al, studied a small
subset of Medicare patients and found that higher morbidity burden was associated with more
medical visits.72 Another limitation in this study is the censoring of cases with cause of death coded
as 777.7; the cause of death for these cases has been provided to KCR by the National Death Index
which restricts use of data and cannot be released.73 It is unknown if the 777.7 coded cases could
have had a CRC related mortality; all of those cases were censored, thus the results of the CRC
mortality Cox proportional hazard models could be skewed. The last limitation is that this study
included stage 0 CRC within the early stage group.
Although progress has been made in the last few decades in understanding CRC, there is still a
paucity of data examining the impact of comorbidities on cancer survival and secondary primary
malignancies in relation to comorbidities. This research identifies that comorbidity burden increases
the hazards of all-cause and CRC mortality. Further direction of research should be to examine the
gap in knowledge of the role that comorbidity burden has on the standards of care and adherence to
care for CRC patients.
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Chapter 4
Paper 2: Spatio-temporal Analysis of Elixhauser Comorbidity Groupings and Stage of
Diagnosis among Colorectal Cancer Cases in Kentucky (2003-2016)
Background
Colorectal cancer (CRC), includes any cancer that affects the large intestine of the
gastrointestinal system, made up of the colon and rectum.7 Previously CRC had a low incidence rate,
however it is now the third most common type of cancer and the third most common cause of cancer
death among men and women in the United States.1-3 The American Cancer Society estimates that
in 2020 there will be 147,950 new cases of CRC and 53,200 deaths from the disease in the U.S..3
Kentucky had the highest CRC incidence in nation with 49.2 (per 100,000) for years 2012-2016 and
ranked 5th in the nation in CRC mortality at a rate of 16.4 (per 100,000) for years 2013-2017.3-6
We do not know the exact cause of CRC, however, there are many known risk factors
associated with CRC2. The risk of developing CRC increases with age, adults over the age of 50 have
the highest CRC burden than any age group.3, 10 Other known risk factors for CRC include family
history, African American race, history of polyps, history of radiation therapy, inherited and
inflammatory diseases, and lifestyle factors like low physical activity, smoking, alcohol consumption,
obesity, and diets consisting of high-fat content.2, 7
The Appalachian region includes the state of West Virginia and counties from 12 other states,
including 54 counties in the eastern half of Kentucky.53, 54 Eastern Kentucky is markedly rural and less
populated than other regions of the state, yet experiences higher rates of mortality and morbidity
than the rest of the state.5 Health disparities have been well documented in rural Appalachia.5, 53
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A comorbidity is defined as a disease or condition that exists simultaneously with another
index condition of interest, in this study CRC is the index condition of interest.38, 39 The presence of
comorbidity with an index condition, like CRC, has become increasingly more common with majority
of the evidence supporting the highest comorbidity burden is concentrated in patients that are older,
in minority groups, and living in poverty stricken areas.39 In this study, comorbidities will be looked
at on an individual level, grouped level, and an Elixhauser comorbidity index count that can be found
in table 2-1. The Elixhauser comorbidity index includes 29 individual comorbid conditions, that were
initially selected and refined by examining the literature.41, 42 Rural Appalachia also experiences high
prevalence rates of stroke, obstructive pulmonary disease, heart disease, and diabetes than nonAppalachian areas.5, 53-55 The most prevalent comorbidity among CRC patients had been found to be
diabetes.8, 9 Patients with diabetes have an estimated 25% increased risk of developing CRC
compared to patients without diabetes.9
Socioeconomic, behavioral, and geographical factors exacerbate health disparities and
disease in Appalachia.53, 55 Socioeconomic factors poverty, low literacy rates, lack of health insurance
coverage, long traveling distances to healthcare providers, behavioral factors such as high rates of
obesity and smoking, low physical activity, and environmental exposures can impact disease
prevalence and screening in Appalachia.5, 53, 55, 74 The distribution of comorbidity across the state is
easier to understand when looking at a map of disease information compared to typical research
tables showing numeric data.58
Geographic information systems (GIS) are used in epidemiological research to identify a visual
location or “where” of disease.58 Spatial data in public health studies aids researchers in visualizing
disease across geographic areas, allowing for easy identification of health trends over time.59, 60
Spatial analysis can help to determine patterns or clusters in geographic areas that that can be used
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to understand patient populations at higher risk and highlight areas for intervention in addressing
health disparities.59, 60, 75
The purpose of the current GIS project is to explore the impact of comorbidities on stage at
diagnosis among CRC patients in Kentucky by examining geographical distribution of comorbidities
and comparing maps of late-stage and cluster analysis. Those included were age 18 and older and
diagnosed between January 1, 2003 and December 31, 2016. To date, there is no known study that
has compared the geographical distribution of CRC stage at diagnosis and comorbidities across
Kentucky or the nation. To address these gaps in the literature, we conducted secondary data analysis
on CRC patients in Kentucky using data from the Kentucky Cancer Registry. The specific aim for this
study was to perform a space-time cluster spatial analysis by mapping cases (late-stage) and controls
(early) of patients by year of diagnosis across Kentucky and investigate geographical distribution of
comorbidities across county at diagnosis. Depending on findings, recommendations for a systematic
approach in using the clusters to identify geographic targets where public health interventions with
screening would be recommended to help reduce the risk of late-stage diagnosis. Late-stage CRC is
considered preventable.76 The outcomes of this study will hopefully highlight the geographic regions
to target that could potentially reduce the number of late-stage diagnoses.

Methods
Study Design and Data Sources
This is a matched case-control study of CRC cases in Kentucky. We started out with 28,229
incident cases of primary CRC diagnosed between January 1, 2003 and December 31, 2016 and
initially excluded a combined total of 7,658 cases due to missing information. Excluded cases were
6,054 with missing morbidity information and 2,730 (1,126 of these were also missing morbidity
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information and included in the above number) with missing stage, leaving a sample size of 20,571
cases. Patients were then matched on a one to one basic by age group (18-49, 50-74, 75+ years) and
sex (M/F) resulting in a total of 18,170 included patients, 9,085 late-stage cases matched to 9,085
early-stage controls. All data were identified from the Kentucky Cancer Registry (KCR). Kentucky is
funded by Surveillance, Epidemiology, and End Results Program (SEER) and National Program of
Cancer Registries (NCPR); the umbrella program, North American Association of Central Cancer
Registries (NAACR), independently evaluates data collected by KCR for completeness, accuracy, and
timeliness.20, 27 Requested data from KCR included first cases of primary CRC. Included cases could
have multiple primaries after initial their CRC, however, any cases with CRC as a primary cancer or
metastasis after another cancer diagnosis was excluded. Approval for this study was granted by the
University of Kentucky Institutional Review Board.
Variables
Sex, age at diagnosis, race, marital status at diagnosis, county at diagnosis, Appalachian status,
vital status, best stage group, comorbidity diagnoses (up to 10 independent variables of ICD-9-CM
diagnosis codes), and secondary diagnoses (up to 10 independent variables of ICD-10-CM diagnosis
codes) were provided by KCR. Age at diagnosis was categorized into three age groups, 18 - 49, 50 74, and 75+ years. Race was categorized as white, black, and other. Marital status at diagnosis was
categorized at married, single, or other. Primary payer was categorized as Medicaid, Medicare,
military/other, private pay, and not insured. County at diagnosis was originally coded with a numeric
identifier and then recoded to match the name of the county in Kentucky; all 120 counties in
Kentucky were represented in the data.
Comorbidity was measured using the comorbidity and secondary diagnosis variables entered
into the Healthcare Cost and Utilization Project’s Elixhauser Comorbidity Software (Version 3.7 for
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ICD-9CM codes and the ICD-10-CM version) created by the Agency for Healthcare Research and
Quality.41, 45 Diagnosis codes were processed using a SAS program macro that classifies Elixhauser
Comorbidity variables, outputting individual binary variables for the 31 (Version 3.7)/29 Elixhauser
morbidity groups. The final variables were combined to match the most up-to-date Elixhauser index.
Exceptions include the omission of any cancer related comorbidities, and combination of the two
diabetes categories (with and without chronic complications) into one.
The Adult Comorbidity Evaluation-27 (ACE-27) index was also considered, but unfortunately
available data did not allow us to grade severity within the ACE-27 index. Regardless, studies have
shown that the Elixhauser measures outperform other comorbidity indices.46, 48, 49, 64, 66 Table 2-1
shows the morbidity mapping used from ACE-27 groups to the Elixhauser Comorbidity index to the
final inclusion of comorbidities (individual and grouped). KCR comorbidity and secondary diagnosis
variables include codes for patients known to have no morbidity (comorbidity diagnosis code of 0000
or a secondary diagnosis entry of 0), patients with corresponding entries in either diagnoses code
variables were treated as having no morbidity. Patients with a diagnosis code in the
comorbidity/secondary diagnosis variables that did not match with an Elixhauser group were also
treated as having no morbidity. Patients lacking comorbidity and secondary diagnosis data were
considered to have unknown morbidity status and thus excluded from the study. Not all facilities
reporting to KCR are part of the Commission of Cancer (CoC), a group that requires comprehensive
standardized data collection including comorbidity information.19, 20 Stage was dichotomized to
reflect early (stage 0, I, II) or late (III and IIII) stage disease. Patients with unknown cancer stage was
also excluded. Patients were then matched one-to-one on age group and sex by cancer stage (early or
late). There were 2,301 more controls than cases and there were 100 cases that did not have enough
controls to match in the corresponding age and sex groups. The 2,401 patients who did not have a
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match were excluded. There were 9,085 cases and controls included in the final analysis. Figure 2-1
shows the flow chart for patient inclusion and exclusion in the study.
Statistical and Spatial Analysis
The statistical software, SAS version 9.4 was used to examine patient demographics and
disease characteristics, and fit a logistic regression model of late-stage diagnosis in relation to each of
the Elixhauser-based comorbidity variables.21 A retrospective space-time cluster analysis using the
Bernoulli case-control model constrained to clusters no larger than 35% of the population at risk and
50% of the study period (2003-2016) was performed with SaTScan software.22 SaTScan was required
to perform the analysis because standard GIS software packages do not have this function.61 The
purpose of SaTScan cluster analysis was to perform a geographical surveillance of CRC to try to detect
areas with high or low rates of significance (Figure 2-4).22 ArcGIS was used for mapping the
comorbidities and proportion of cancers that were late-stage within each county, and mapping the
cluster found in the SaTScan analysis.23 Thus we use both SaTScan and ArcGIS to complement to
each other, we exported the cluster analysis file and joined to ArcGIS for mapping purposes.62
Data were aggregated based on county. The number of aggregated late-stage cases within
each county were then divided by the total of cases and controls (early-stage) within each county,
this gave us the proportion to map. The comorbidity maps were designed the same way, individual
comorbidity aggregated counts were divided by the total number of cases and controls in each
county, and combined late and early-stage percentage of two or more comorbidities were also
treated this way. All maps used the data classification of Jenks natural breaks. Natural breaks are data
specific classifications that are based on natural groupings within the data with similar values, they
are used as a means to maximize differences between the classification percentages.77
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Table 2-1. Morbidity Mapping ACE-27 Index, Elixhauser, and Final Inclusion Study Comorbidity and
Groupings
Ace-27 Index

Elixhauser ICD 10*

Final Inclusion

Cardiovascular System
Congestive Heart Failure
Cardiovascular System
Myocardial Infarct
Valvular disease
Congestive Heart Failure
Angina / Coronary Artery Disease
Pulmonary circulation disorders
Hypertension
Congestive Heart Failure (CHF)
Peripheral vascular disease
Peripheral Vascular Disorder
Arrhythmias
Hypertension (Complicated &
Valvular Heart Disease
Hypertension
Uncomplicated)
Respiratory System
Venous Disease
Paralysis
Pulmonary Circulation Disorders
Peripheral Arterial Disease
Other neurological disorders
Chronic Pulmonary
Chronic pulmonary disease
Respiratory System
Gastrointestinal System
Diabetes Uncomplicated
Restrictive Lung Disease or COPD
Liver Diseases
Diabetes Complicated
Other markers not diagnoses
Peptic Ulcer Disease
Hypothyroidism
Gastrointestinal System
Renal System
Renal failure
Hepatic
Renal Failure
Liver disease
Stomach / Intestine
Endocrine System
Chronic peptic ulcer disease
Pancreas
Diabetes (Complicated & Uncomplicated)
HIV and AIDS
Hypothyroidism
Renal System
Lymphoma
End-stage renal disease
Neurological System
Metastatic cancer
Endocrine System
Paralysis
Solid tumor without metastasis
Other Neurological Disorders
Diabetes Mellitus
Rheumatoid arthritis/ collagen vascular
Neurological System
Psychiatric
diseases
Stroke
Psychoses
Coagulation deficiency
Dementia
Depression
Obesity
Paralysis
Rheumatologic
Weight loss
Neuromuscular
Rheumatoid Arthritis/Collagen
Fluid and electrolyte disorders
Psychiatric
Immunological System
Recent suicidal attempt
Blood loss anemia
AIDS/HIV
Schizophrenia
Deficiency anemias
Substance Abuse
Depression or bipolar disorder
Alcohol abuse
Alcohol Abuse
Rheumatologic
Drug abuse
Drug Abuse
Rheumatoid Arthritis
Psychoses
Body weight
Systemic Lupus
Depression
Obesity
Mixed Connective Tissue Disorder
Blood System
Polymyositis
Coagulopathy
Rheumatic Polymyositis
Blood Loss Anemia
Immunological System
Deficiency Anemia
AIDS
Remain but not grouped
Malignancy
Weightloss
Solid Tumor including melanoma
Leukemia and Myeloma
Fluid & Electrolyte Disorders
Lymphoma
Substance Abuse
Alcohol
Illicit Drugs
Body Weight
Obesity
*Elixhauser ICD-9 (31 Variables) conversion to ICD-10 (29 Variables) version changes: Removal of Cardiac Arrhythmia and
Combining of Hypertension with and without complications. Some data were collected prior to the 2015 ICD-10 activation,
combination and conversion of ICD-9 and ICD-10 Elixhauser adjustment occurred.
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Table 2-2. Patient Demographics
Demographics
Age
18 - 49 years
50 – 74 years
75+ years
Marital Status
Missing
Married
Single
Other
Sex
Female
Male
Race
White
Black
Other
Diabetes
Renal Failure
Liver Disease
CHF
Hypertension
Appalachian
Total Comorbidity Groups
0
1
2+
Vital Status
Alive
Dead

Early Stage (I-II)
(N=9085)

Late Stage (III – IV)
(N=9085)

2,157 (11.87%)
11,186 (61.56%)
4,827 (26.57%)

1,128 (12.42%)
5,625 (61.92%)
2,332 (25.67%)

184 (2.03%)
5,269 (58.00%)
972 (10.70%)
2,660 (29.28%)

191 (2.10%)
5,079 (55.91%)
1,026 (11.29%)
2,789 (30.70%)

4,374 (48.15%)
4,711 (51.85%)

4,374 (48.15%)
4,711 (51.85%)

8,360 (92.02%)
668 (7.35%)
57 (0.63%)
1,998 (21.99%)
362 (3.98%)
277 (3.05%)
780 (8.59%)
4,983 (54.85%)
2,462 (27.10%)

8,374 (92.17%)
646 (7.11%)
65 (0.72%)
1,653 (18.19%)
290 (3.19%)
328 (3.61%)
601 (6.62%)
4,053 (44.61%)
2,570 (28.29%)

1,357 (14.94%)
2,880 (31.70%)
4,848 (53.36%)

2,283 (25.13%)
2,443 (26.89%)
4,359 (47.98%)

5,439 (59.87%)
3,646 (40.13%)

2,964 (32.63%)
6,121 (67.37%)
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Figure 2-1. Flow chart for participant selection and inclusion/exclusion criteria for matched study
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Results
The choropleth morbidity maps, found in Figure 2-2, show the geographical distribution of the
four individual comorbidities, electrolyte disorders, liver disease, weight loss, and deficiency anemia
across Kentucky. The four maps do not demonstrate any geographical patterns in the distribution of
comorbidities. The map of comorbidities among CRC patients is displayed in Figure 2-3. This map
shows that a large percentage of CRC patients experience two or more comorbidities, but does not
demonstrate a strong pattern of disease.
The percentage of late-stage cancer by county appears in Figure 2-4 with a retrospective
space-time cluster analysis utilizing SaTScan found one cluster with the highest likelihood and
statistically significant high-rate cluster of late-stage CRC in southeastern Kentucky. The time period
for this cluster was limited to January 1, 2013 to December 31, 2016. This map does not exhibit a
strong geographical pattern of late-stage cancer, but does show there is a high burden of late-stage
CRC within the majority of the counties and within the cluster area. There were 751 total observed
late-stage cases, while the expected number of late-stage cases was only 612.5, a ratio of 1.23
observed late-stage diagnoses for each one expected(p <0.0001).
The bivariate model results in Table 2-2 show that some individual comorbidities had a
protective effect with regard to late-stage diagnosis of CRC, while other comorbidities appeared to be
a risk factor for late-stage diagnosis of CRC. The individual comorbidities with statistically significant
reduced odds of late-stage CRC were found in CHF (OR= 0.754, 95% CI 0.675-0.842), valvular disorder
(OR= 0.725,95% CI 0.597 - 0.881), peripheral vascular disease (OR= 0.762, 95% CI 0.644 - 0.902),
hypertension (OR= 0.663, 95% CI 0.625 - 0.703), neurological disorders excluding paralysis (OR=
0.821, 95% CI 0.706 - 0.956, chronic obstructed pulmonary disease (OR= 0.746, 95% CI 0.688 - 0.809,
diabetes (OR= 0.789, 95% CI 0.734 - 0.849, hypothyroidism (OR= 0.769, 95% CI 0.679 - 0.871), obesity
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(OR= 0.774, 95% CI 0.682 – 0.879), and renal failure (OR= 0.795, 95% CI 0.679 - 0.930. The individual
comorbidities with statistically significant increased odds of late-stage CRC were found in liver disease
(OR= 1.191, 95% CI 1.012 - 1.401, weight loss (OR= 1.593, 95% CI 1.400 - 1.813), electrolyte (OR=
1.187, 95% CI 1.087 - 1.296, and deficiency anemia (OR= 1.113, 95% CI 1.033 - 1.199. When
aggregating the total number of individual morbidities, grouped as 0, 1, or 2+ comorbidities, having a
comorbidity had a protective effect against the odds of late-stage diagnosis of CRC compared to
those without a comorbidity. Having one comorbidity (OR= 0.504 95% CI 0.463 - 0.550) reduced the
odds of late-stage diagnosis of CRC by 49.6% and having two or more total comorbidities (OR= 0.534,
95% CI 0.494 - 0.578) reduced the odds of late-stage diagnosis of CRC by 46.6% compared to those
who did not have a comorbidity.
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Figure 2-2. Choropleth mapping percentage of Kentucky CRC patients diagnosed with individual
comorbidity within each county 2003-2016
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Figure 2-3. Kentucky CRC patients having been diagnosed January 1, 2003 – December 31, 2016
with 2 or more comorbidities by county

Figure 2-4. Late Stage CRC by County and Retrospective Space-Time Analysis High Rate Cluster of
Late Stage CRC in Kentucky diagnosed from January 1, 2013 – December 31, 2016

62

Table 2-3. Elixhauser Based Morbidity Bivariate
Elixhauser Bivariate

Late Stage (III – IV)
(Event =1) OR (95% CI)
0.754 (0.675 - 0.842)***
0.725 (0.597 - 0.881)**
0.911 (0.713 - 1.164)
0.762 (0.644 - 0.902)**
0.663 (0.625 - 0.703)***
0.892 (0.609 - 1.308)
0.821 (0.706 - 0.956)*
0.746 (0.688 - 0.809)***
0.789 (0.734 - 0.849)***
0.769 (0.679 - 0.871)***
0.795 (0.679 - 0.930)**
1.191 (1.012 - 1.401)*
1.040 (0.757 - 1.430)
1.154 (0.549 - 2.426)
0.857 (0.652 - 1.126)
1.093 (0.830 - 1.440)
0.774 (0.682 - 0.879)***
1.593 (1.400 - 1.813)***
1.187 (1.087 - 1.296)**
1.014 (0.877 - 1.173)
1.113 (1.033 - 1.199)**
0.944 (0.747 - 1.194)
0.804 (0.532 - 1.214)
1.099 (0.827 - 1.460)
0.969 (0.849 - 1.105)

CHF
Valvular Disorder
Pulmonary Circulation
Peripheral Vascular
Hypertension
Paralysis
Neurological
Chronic Pulmonary
Diabetes
Hypothyroid
Renal Failure
Liver Disease
Peptic ulcer
Aids
Rheumatoid Arthritis
Coagulopathy
Obesity
Weight loss
Electrolyte
Blood loss Anemia
Deficiency Anemia
Alcohol Abuse
Drug Abuse
Psychosis
Depression
Total # of Morbidity Groups
0
Ref
1
0.504 (0.463 - 0.550)***
2+
0.534 (0.494 - 0.578)***
* p < 0.05 ; ** p < 0.01 ; *** p < 0.0001

Discussion
While the results show that comorbidities are associated with a lower risk of late-stage
disease, and that there is a cluster of counties in the southeastern region of Kentucky with a higher
proportion of late-stage cancer cases than expected, the study did not discern a geographical pattern
suggesting that comorbidities were similarly distributed. It seems more likely that other factors are
driving the higher rates of late-stage CRC in these counties.
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There is no clear indication from the data of what might be driving the higher rates of latestage CRC in the cluster, however, more complete records for the excluded cases may have provided
more information to the area, as just over 40% of the excluded records were from Appalachian
counties. There are inherit barriers in the Appalachian area that has long been acknowledged as
issues related to disparities in CRC screening. CRC screening barriers in this area is complex and
interrelated to each other, from cultural beliefs and values, demographic factors, and psychological
factors surrounding CRC and screening.56, 78, 79 There are knowledge gaps, which can be related to not
knowing family history, having a less than high school education, and males in general having overall
low knowledge about CRC.78, 79 There is also a cultural and religious belief that while medical exams
are important, the more men knew about CRC screening involves they no longer related the exam
with health, rather they associated the screening negatively because they believe the invasiveness of
the experience relates to their masculinity.78-80
While the maps do not show that there is a pattern of comorbidity corresponding to the
cluster, they do show that a large percentage of patients diagnosed with initial primary CRC
experience disproportionate rates of comorbidities. The map of aggregate comorbidities does not
appear distributed in any particular pattern, but shows that more than half of CRC patients have
multiple comorbidities in a majority of counties (73 out of 120).
There are several limitations to this study. The first is potential selection bias. There were
28,229 patients diagnosed with first primary CRC during the study time period that were identified by
KCR. After removals due to missing data, comorbidities and stage at diagnosis, and the inability to
matched one to one (cases and controls) on age and sex, the final total was 18,170 patients, an
exclusion of 10,059 or 35.6% of the total identified patients. One reason for the large amount of
missing comorbidities could be because many of the facilities reporting may not be hospitals that are
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part of the Commission of Cancer (CoC) with comprehensive standardized data collection.19, 20
Another major limitation of the study is the notion of ecological fallacy. Association observed at an
aggregated scale may not always exist at the individual scale; given the aggregated nature of data in
this study, ecological fallacy is likely present.81 We can see from the bivariate logistic regression that
there are statistically significant associations between late-stage diagnosis and several individual
comorbidities. The third limitation is the likelihood of the under-ascertainment of comorbidities.
Documented comorbidities are from the time of diagnosis, the comorbidities identified from the
reporting facility and physician may not fully capture all comorbidities that the patient had been
diagnosed with prior to the diagnosis of primary CRC. Administrative data has been found to be
associated with under-reporting number of comorbidities compared to chart reviews and clinical
billing codes.82 There were other clusters found in addition to the one reported, however, the one
reported was the hierarchically the cluster with the highest likelihood.22 The other clusters were not
reported in this study because they are considered secondary.22
The logistic regression did have statistically significant results related to individual and
grouped comorbidities. Those comorbidities with reduced odds of late-stage CRC were CHF, valvular
disorder, hypertension, peripheral vascular disease, neurological disorders excluding paralysis,
chronic obstructed pulmonary disease, diabetes, hypothyroidism, and renal failure. The
comorbidities with increased odds of late-stage CRC diagnosis were liver disease, weight loss,
electrolyte disorders, and deficiency anemia. In the aggregated comorbidity variable, those CRC
patients with one or more comorbidities has statistically significant higher odds of late-stage CRC
compared to those CRC patients with no comorbidity. A study by Starfield et al, examined the
impact of comorbidity on the use of primary and specialty care services, finding that higher morbidity
burden was associated with more medical visits in a small subsample of Medicare beneficiaries.72
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Perhaps there is a potential for the types of comorbidities that provide a protective effect
from late-stage CRC require less focus and time from a physician, offering the patient an opportunity
to mention other symptoms that may trigger a physician to screen a patient for cancer.83, 84 It may
also be that patients with these comorbidities return regularly for routine health checks, and thus
have more opportunities for screening. On the other hand, it is possible that comorbidities associated
with increased odds of late-stage diagnosis have “competing demand”, where a physician’s time and
vigilance are focused on dealing with complex comorbidities that require urgent attention and
interfere with preventive services like cancer screening.83, 84 Further research into comorbidities and
CRC are needed. In particular chart reviews and examination of clinic billing codes could aid in
determining the number of times a patient sought care, and how long they had been diagnosed with
comorbidities before CRC diagnosis.
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Chapter 5
Conclusion
This research aimed to 1) characterize the patient factors of socio-demographic and
comorbidity by stage of diagnosis, 2) examine if comorbidity status is associated with mortality and
the development of second primary cancers, and 3) to perform a space-time cluster analysis of latestage at diagnosis to investigate its relationship with comorbidities at the population level. The
results of the two studies are varied. Based on the bivariate regression analysis in both the GIS and
research paper, comorbidity burden does seem to play a role in predicting stage, many of the
individual comorbidities are protective, or have reduced odds of late-stage CRC. The Cox hazard
regressions show that many of the individual comorbidities have an increased hazard of all-cause and
CRC mortalities. There does appear to be a dose-response relationship in the Cox models, suggesting
that the progression from individual to aggregated comorbidities there is a relationship with having
any comorbidity and the outcome of mortality. The space-time analysis found a significant high rate
cluster of late-stage CRC, however, mapping the distribution of positively associated comorbidities,
individually or in aggregate count, did not demonstrate a pattern matching the cluster.
The results indicate that comorbidities do play a role in the stage of CRC diagnosis,
perhaps curiously, there are greater odds of being diagnosed with early-stage cancer for many of the
individual comorbidities. On the other hand, the results also indicate that some comorbidities
increase the hazards of mortality and second primary malignancy. Although there is a defined cluster
of higher than expected late-stage CRC in southeastern and eastern Kentucky, at this aggregate level,
the results do not indicate that there is a geographically distributed pattern of comorbidities that
appear to affect the CRC cluster. The results do show nonetheless that there is a larger number of
CRC patients across a majority of Kentucky counties who suffer from comorbidity burden.
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There were noted limitations of selection bias, ecologic fallacy, and potential underascertainment of comorbidity information for the cases. There was a high percentage of cases
excluded to missing data with a high percentage from Appalachia. Perhaps more complete data from
Appalachia would have shed light on the area where the space-time CRC cluster was discovered.
Further research is needed to examine why having certain comorbidities would be protective
of late-stage diagnosis, could those patients be more likely to visit a doctor and therefore have a
higher likelihood of being screened for cancer than the people who did not have these protective
comorbidities? Further research needs to be done to try to determine what factors are driving the
high rates of CRC in the area of the indicated cluster. Future research topics should include
investigating the number of times CRC patients sought care, and how long they’d been diagnosed
with comorbidities before CRC diagnosis, this would allow a Cox regression model to examine a time
to event, the time a patient was diagnosed with a comorbidity until the time they were diagnosed
with the event, cancer.
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